EPA Public Access

Author manuscript

Pharmacol Ther. Author manuscript; available in PMC 2019 February 26.

About author manuscripts

Submit a manuscript

Published in final edited form as:

Pharmacol Ther. 2016 September ; 165: 63–78. doi:10.1016/j.pharmthera.2016.05.006.

The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction

Elizabeth A. W. Chan¹, Barbara Buckley², Aimen K. Farraj³, and Leslie C. Thompson³

¹Oak Ridge Institute for Science and Education (ORISE) Fellow at the National Center for Environmental Assessment, U.S. Environmental Protection Agency (EPA), Research Triangle Park, NC, USA.

²National Center for Environmental Assessment, U.S. EPA, Research Triangle Park, NC, USA.

³Environmental Public Health Division, U.S. EPA, Research Triangle Park, NC, USA.

Abstract

Exposure to particulate matter air pollution has been causally linked to cardiovascular disease in humans. Several broad and overlapping hypotheses describing the biological mechanisms by which particulate matter exposure leads to cardiovascular disease have been explored, although linkage with specific factors or genes remains limited. These hypotheses may or may not also lead to particulate matter-induced cardiac dysfunction. Evidence pointing to autocrine/paracrine signaling systems as modulators of cardiac dysfunction has increased interest in the emerging role of endothelins as mediators of cardiac function following particulate matter exposure. Endothelin-1, a well-described small peptide expressed in the pulmonary and cardiovascular systems, is best known for its ability to constrict blood vessels, although it can also induce extravascular effects. Research on the role of endothelins in the context of air pollution has largely focused on vascular effects, with limited investigation of responses resulting from the direct effects of endothelins on cardiac tissue. This represents a significant knowledge gap in air pollution health effects research, given the abundance of endothelin receptors found on cardiac tissue and the ability of endothelin-1 to modulate cardiac contractility, heart rate, and rhythm. The plausibility of endothelin-1 as a mediator of particulate matter-induced cardiac dysfunction is further supported by the therapeutic utility of certain endothelin receptor antagonists. The present review examines the possibility that endothelin-1 release caused by exposure to PM directly modulates extravascular effects on the heart, deleteriously altering cardiac function.

Corresponding author: Leslie C. Thompson, Ph.D., U.S. Environmental Protection Agency, 109 T.W. Alexander Dr., Research Triangle Park, NC 27711, Mail Code: B105-02, Phone: (919) 541-4767, Fax: (919) 541-0034, thompson.leslie@epa.gov.

Contributions

E. A. W. Chan and L. C. Thompson developed the idea for the manuscript and E. A. W. Chan wrote the first draft. B. Buckley, A. K. Farraj, and L.C. Thompson performed extensive revisions, and all authors have approved the final manuscript.

Conflict of Interest Statement

The authors declare that there are no conflicts of interest.

Publisher's Disclaimer: Disclaimer

The views expressed in this article are those of the authors and do not necessarily represent the views or opinions of the U.S. EPA. Mention of or referral to commercial products does not imply official EPA endorsement of or responsibility for the products, or guarantee the validity of the information provided.

Keywords

Cardiac dysfunction; particulate matter; air pollution; endothelin-1; heart; autocrine/paracrine signaling

1. Introduction

Cardiovascular disease (CVD) encompasses many pathologies of the blood vessels and/or the heart. CVD includes stroke, coronary artery diseases (such as angina and heart attacks), hypertension, atherosclerosis, and cardiac dysfunction. CVD is the leading cause of mortality, causing one out of four deaths in the United States (US) (CDC, 2015) and ~30% of deaths (~17.5 million people in 2012) worldwide (WHO, 2014a).

2. Particulate matter exposure and cardiovascular disease

2.1 Particulate matter air pollution

Of the 17.5 million CVD-related deaths in 2012, ~3 million were associated with exposure to ambient air pollution (WHO, 2014a, 2014b). Ambient air contains a complex mixture of particulate matter (PM), gases (e.g., nitrogen dioxide [NO₂], carbon monoxide, sulfur dioxide [SO₂], ozone [O₃]), semivolatile and volatile organics, and other pollutants which can vary by source, location, time of day, and season. Although PM is derived in part from natural sources such as pollen dust and volcanic ash, anthropogenic sources including motor vehicle emissions and power plants are the major sources of concern, as PM released from these sources is thought to contain high levels of pro-oxidant organics (e.g., polyaromatic hydrocarbons) and transition metals (e.g., iron, nickel, vanadium).

PM varies by size, solubility, particle number, atmospheric/biological stability, source, and charge, which may all be determinants of toxicity potential. The smaller the particle, the higher the surface area-to-mass ratio and the greater the potential for adsorption of substances (e.g., metals, endotoxin, and organic compounds) that can modulate the biological effects and/or toxicity of PM (US EPA, 2009). PM has long since been recognized as a threat to human health, with the US Environmental Protection Agency (EPA) promulgating both short-term (24 hour) and long-term (annual) National Ambient Air Quality Standards since 1971 (36 FR 8186).

PM is heterogeneous in size and is commonly described by nominal aerodynamic diameter in microns (μm). Whereas the diameter of a human hair is approximately 100 μm and the limit of human vision is about 50 μm, coarse particles (PM₁₀) are 10 μm in diameter, fine particles (PM_{2.5}) are 2.5 μm and ultrafine particles (UFP) have a diameter of 0.1 μm (Brook, Franklin, et al., 2004; WHO, 2003). In humans, the site and amount of PM deposition is highly influenced by inhalation route (nasal vs. oronasal) and inhaled particle size fraction (Brown, Gordon, et al., 2013). Generally, nasal inhalation is associated with reduced particle penetration into the lower respiratory tract. With regard to particle size fractions, UFP and PM_{2.5} deposit throughout the respiratory tract, whereas coarse particles (nominal mean particle size between 2.5 and 10 μm) largely deposit in the upper respiratory tract and to a lesser extent in the lungs.(US EPA, 2009)

2.2 Air pollution and cardiovascular disease

Multiple lines of evidence over the last several decades have demonstrated associations between PM exposure and CVD, and in 2009 the US EPA determined that a causal relationship exists between short- and long-term exposures to PM_{2.5} and cardiovascular (CV) effects in humans (US EPA, 2009).

2.2.1 Mortality—Evidence of a relationship between ambient air pollution and adverse human health consequences date back to the early 1900s. One of the first documented events demonstrating that air pollution was directly associated with morbidity and mortality occurred in December 1932, when a thick fog covered an industrialized region of Belgium for five days and 60 people died (Nemery, Hoet, et al., 2001). Twenty years later a similar event caused the London Smog of 1952, in which daily average smoke PM concentrations reached >4 mg/m³ (Scott, 1953). Up to 12,000 deaths were attributed to this smog event (Bell, Davis, et al., 2004).

The initial realization that exposure to polluted air was associated with increased mortality has been supported by multiple long-term prospective air pollution studies. The Harvard Six Cities Study evaluated >8000 subjects and showed an association between air pollution (estimated using a single outdoor monitor at each location) and mortality due to lung cancer and cardiopulmonary disease (Dockery, Pope, et al., 1993). Two years later an analysis of the American Cancer Society Cancer Prevention II (ACSCPII) cohort presented similar findings from >500,000 individuals residing in all US states (Pope, Thun, et al., 1995). Specifically, ambient PM_{2.5} and sulfate particulate air pollution were associated with all-cause, cardiopulmonary, and lung cancer mortality. Deaths in the ACSCPII cohort were related to ischemic disease, arrhythmias, heart failure (HF), and myocardial infarction (MI). Follow-up and reanalysis of both studies have strengthened the original conclusions (Jerrett, Burnett, et al., 2013; D. Krewski, R. T. Burnett, et al., 2005; D. Krewski, R. Burnett, et al., 2005; Laden, Schwartz, et al., 2006; Lepeule, Laden, et al., 2012; Pope, Turner, et al., 2015; Turner, Krewski, et al., 2011).

One of the largest (>2 million Canadian subjects) studies of chronic PM exposure to date found an association between PM_{2.5} and mortality in a retrospective cohort (Crouse, Peters, et al., 2012). This finding was especially compelling as the association was observed with exposures to relatively low estimated mean PM_{2.5} concentrations (mean, 8.7 µg/m³; interquartile range, 6.2 µg/m³). Although the relative risk of ambient air pollution was small, a meta-analysis of 11 long-term air pollution exposure and mortality publications found a pooled effect estimate of 6% (95% CI: 4, 8%) for all-cause and 11% (95% CI: 5, 16%) for CV mortality, per 10 µg/m³ increase in PM_{2.5} exposure (Hoek, Krishnan, et al., 2013). As nearly everyone is exposed to air pollution, even a small relative risk equates to a large number of individuals that will develop CVD from exposure to air pollution.

A large body of peer-reviewed literature that chronicled the effects of short-term exposure (< 1 week) has used time-series analyses to provide strong supporting evidence connecting PM to morbidity and mortality. The National Morbidity, Mortality, and Air Pollution Study was performed in 100 cities in the US and observed PM exposure-related mortality (Peng, Dominici, et al., 2005). Regarding PM₁₀, a study of 16 cities in China with relatively high

concentrations (52 to 156 $\mu\text{g}/\text{m}^3$) found associations with CV and respiratory mortality (R. Chen, Kan, et al., 2012). In the same study, females, people over the age of 64, and residents with less education appeared to be at increased risk of health effects caused by PM_{10} exposure, suggesting that PM air pollution can also exacerbate CV disease in at-risk populations. Relatively low $\text{PM}_{2.5}$ levels in the Greater Boston area were associated with ischemic stroke, with an increase of just 6.4 $\mu\text{g}/\text{m}^3$ $\text{PM}_{2.5}$ elevating the odds ratio by 1.11 (95% CI: 1.03–1.20) (Wellenius, Burger, et al., 2012).

2.2.2 Vascular disease and atherosclerosis—Findings from the large Multi-Ethnic Study of Atherosclerosis (MESA) and Framingham cohorts have shown that chronic exposure to low levels of PM was associated with vasoconstriction and endothelial dysfunction (Krishnan, Adar, et al., 2012; Wilker, Ljungman, et al., 2014). Long-term $\text{PM}_{2.5}$ exposure in the MESA cohort members was also associated with arterial wall thickening and the development of systemic atherosclerosis, with a 5 $\mu\text{m}/\text{year}$ increase in carotid intima-media thickness for each 2.5 $\mu\text{g}/\text{m}^3$ increase in $\text{PM}_{2.5}$ (Adar, Sheppard, et al., 2013). These findings are in agreement with studies of increased carotid intima-media thickness in elderly men in Boston (Wilker, Mittleman, et al., 2013) and adults in Spain (Rivera, Basagana, et al., 2013) exposed to varying levels of traffic-related PM.

2.2.3 Heart failure—Changes in activity level require rapid increases and decreases in cardiac output to maintain a sufficient supply of oxygenated blood. HF occurs when the heart is unable to pump sufficient amounts of blood to meet the oxygenation needs of the body, and was the leading cause of Medicare-funded hospitalizations in 2010 (Pfunter, Wier, et al., 2013). HF can be chronic and, when accompanied by edema, congestive. Congestive HF occurs when fluid moves out of the vasculature more quickly than it can be returned by the lymphatic system, due to an increase of pressure in the veins resulting from low cardiac output (Cho & Atwood, 2002).

The ACSCPII cohort is one of the few that assessed HF mortality, finding an association with long-term $\text{PM}_{2.5}$ exposure (Pope, Burnett, et al., 2004). Short-term exposure to PM has also been linked to HF hospitalizations. Hospital admissions records from 11.5 million Medicare enrollees living near (average distance of 6 miles) a $\text{PM}_{2.5}$ monitor experienced a 1.28% (95% CI: 0.78–1.7895%) increase in HF-related hospital admission per 10 $\mu\text{g}/\text{m}^3$ increase in $\text{PM}_{2.5}$, the largest increase found in the study (Dominici, Peng, et al., 2006). Interestingly, higher exposure to traffic-related air pollution was associated with an increased mortality rate in those with HF (Medina-Ramon, Goldberg, et al., 2008). In agreement, a reduction in $\text{PM}_{2.5}$ exposure was associated with a decrease in HF hospitalizations (Dominici, Peng, et al., 2006). Finally, a meta-analysis of short-term air pollution exposure found for every 10 $\mu\text{g}/\text{m}^3$ increase in $\text{PM}_{2.5}$ there was a 2.12% (95% CI: 1.42–2.82%) increase in HF hospitalization or death (Shah, Langrish, et al., 2013).

2.2.4 Heart rate variability—Heart rate variability (HRV) has been a useful health outcome measured in response to both short- and long-term exposure to air pollution. HRV is a measure of the variability in the time between heart beats, and an indirect indicator of autonomic tone, making it a valuable prognostic indicator of CV well-being (Task Force of the European Society of Cardiology, 1996). Decreased HRV denotes a shift toward increased

sympathetic tone and can be used as a biomarker of increased risk for CV morbidity and mortality.

A recent meta-analysis of 29 epidemiologic studies evaluated the relationship between HRV and short-term air pollution exposure (Pieters, Plusquin, et al., 2012). The report concluded that multiple measures of HRV were consistently inversely associated with PM_{2.5} air pollution exposure. In addition, controlled human exposure studies have shown that the timing of reductions in HRV occur quickly, within minutes to hours of air pollution exposure (Brook, Rajagopalan, et al., 2010; Brook, Bard, et al., 2014), potentially providing insight into the mechanism behind this change.

2.3 Mechanisms of particulate matter exposure-induced cardiovascular dysfunction

As the body of literature connecting PM air pollution to CVD continues to grow, so does interest in the biological mechanisms involved. An understanding of the mechanisms behind PM-induced CVD at all biologic levels, including molecular, cellular, tissue, and organ, could provide biologic plausibility for the epidemiological findings and thus guide air quality policies and decision making.

Three broad and potentially overlapping mechanisms have been proposed to explain how PM inhalation may lead to overt, subacute, subchronic, and chronic responses in the CV system (Franklin, Brook, et al., 2015). These pathways are: (1) pulmonary/systemic inflammation and oxidative stress, (2) autonomic nervous system (ANS) dysregulation/imbalance, and (3) translocation/absorption of PM and/or its components into the bloodstream and transport to other areas of the body. Though each pathway is associated with certain CV outcomes and occurs over a different time frame, there is likely significant cross-talk between the pathways. For example, the ANS can signal through adrenergic receptors on immune cells to mediate inflammation (Bellinger & Lorton, 2014; Forsythe, 2015).

Many PM constituents (e.g., metals and quinones) have been shown to generate reactive oxygen species, capable of causing oxidative stress (Jeng, 2010; Kelly, 2003; N. Li, Xia, et al., 2008; P. Moller, Jacobsen, et al., 2010). Additionally, PM can increase pulmonary (Hao, Comier, et al., 2003; Jin, Shelburne, et al., 2011; N. Li, Harkema, et al., 2010) and systemic (Fujii, Hayashi, et al., 2002; van Eeden & Hogg, 2002; Zhao, Gao, et al., 2013) proinflammatory cytokine levels, including C-reactive protein, tumor necrosis factor- α , and interleukin-6 (Brook, Rajagopalan, et al., 2010). Following alveolar macrophage and/or dendritic cell uptake of PM, cytokine release by phagocytic cells can stimulate bone marrow production of white blood cells, such as neutrophils and leukocytes (Bouthillier, Vincent, et al., 1998; Fujii, Hayashi, et al., 2002; Hiraiwa & van Eeden, 2013; Hiura, Kaszubowski, et al., 1999; van Eeden & Hogg, 2002). Regarding timing, PM-induced inflammation typically occurs hours to days after exposure (Delfino, Staimer, et al., 2008). Local inflammatory responses in the lung can then ‘spill over’ into the circulation, causing systemic oxidative stress and inflammation characterized by an increase in activated white blood cells, platelets, and cytokine expression. Systemic inflammation can then lead to vasoconstriction, increased thrombogenicity and coagulation, endothelial injury, and later atherosclerotic plaque

progression, coronary vasospasm, and myocardial ischemia (Brook, Rajagopalan, et al., 2010).

The ANS is involved in the involuntary control of functions such as HR, which must quickly adjust in response to activity level changes. ANS activation may account for many changes in cardiac function occurring after PM exposure, such as HR, blood pressure (BP), and cardiac arrhythmias. ANS-mediated changes can occur within seconds of activation, potentially accounting for the near-immediate (0–4 hours) manifestation of certain CV effects (Brook, Urch, et al., 2009; Peretz, Sullivan, et al., 2008; Peters, Dockery, et al., 2001). Air pollution exposure may modulate the ANS through the activation of sensory afferent nerves that are triggered by the nociceptive transient receptor potential cation channel member A1 (TRPA1), an ion channel found on the surface of many nerves and other cells in the respiratory tract. When activated, TRPA1 can mediate ANS imbalance and CVD (Ghelfi, Rhoden, et al., 2008). For example, exposure to diesel exhaust (DE), a mixture of air pollutants including PM, increased the sensitivity of rat hearts to triggered arrhythmias, which was abrogated upon TRPA1 signaling blockade (Hazari, Haykal-Coates, et al., 2011).

PM and/or its constituents may also translocate directly to sites of CV dysfunction, such as the heart. Several animal studies provide evidence that PM and/or soluble particle constituents translocate into, directly interact with, and impact CV tissues (Furuyama, Kanno, et al., 2009; Kreyling, Semmler, et al., 2002; Takenaka, Karg, et al., 2001). This pathway may also mediate systemic inflammation, as PM could initiate local inflammation/oxidative stress after extrapulmonary translocation.

2.4 An emerging mechanism of cardiac dysfunction

In this review, we propose that altered autocrine/paracrine signaling, specifically that of the endothelin (ET) system, is a direct cause of cardiac dysfunction following PM exposure. While there may be several autocrine/paracrine agents involved in the spectrum of cardiac dysfunction associated with PM exposure, ET is a likely candidate as the ET system is activated in the pulmonary and CV systems following PM exposure (Finch & Conklin, 2015; Levin, 1995). In addition, ETs mediate several cardiac responses, and thus may be a key mediator of cardiac dysfunction following PM exposure.

3. Particulate matter air pollution and endothelin production

3.1 The endothelin system

The ET system is composed of at least four ET isoforms (Inoue, Yanagisawa, Kimura, et al., 1989) and at least two ET receptors (ETR) (Masaki, Vane, et al., 1994). ET signaling is primarily known for inducing vasoconstrictive effects (Levin, 1995), which can be countered by nitric oxide (NO) (Palmer, Ferrige, et al., 1987). In addition to vessel constriction, ETs can also mediate several physiological functions outside of the vasculature, such as within the heart.

3.1.1 Endothelin-1—Of the ET isoforms, ET-1 is the most abundant in the human CV system and exerts the greatest vasoconstrictive effects (Kedzierski & Yanagisawa, 2001; Luscher & Barton, 2000). In addition to being the most potent and long-lasting

vasoconstrictive peptide currently known (Yanagisawa, Kurihara, et al., 1988; Yanagisawa, Inoue, et al., 1988), ET-1 is also involved in development (Clouthier, Williams, et al., 2000; Kedzierski & Yanagisawa, 2001), immune system regulation (Nett, Teixeira, et al., 2006), glucose sensitivity (Lteif, Vaishnava, et al., 2007), kidney function (Kohan, 2006), brain function (Kedzierski & Yanagisawa, 2001), and cardiac function (Brutsaert, 2003). The majority of ET-1 is released by vascular endothelial cells, although expression level can be modulated by stretch, shear stress, hypoxia, and the presence of factors such as NO (Inoue, Yanagisawa, Takuwa, et al., 1989; Inoue, Yanagisawa, Kimura, et al., 1989; Kedzierski & Yanagisawa, 2001; Malek, Zhang, et al., 1999; Yoshimoto, Ishizaki, et al., 1991). Expression can also be induced in smooth muscle (Hahn, Resink, et al., 1990), macrophages (Ehrenreich, Anderson, et al., 1990), fibroblasts, neurons (Kedzierski & Yanagisawa, 2001; Luscher & Barton, 2000), and cardiomyocytes (H. Ito, Hirata, et al., 1993).

Several lines of evidence suggest that ET-1 functions as an autocrine/paracrine regulator of smooth muscle cells, as opposed to a circulating agent. Biologically active ET-1 levels within the vascular walls can be more than 100-times greater than typically present in human serum (~1–2 pg/ml) (Kedzierski & Yanagisawa, 2001; Shaw, Schmid, et al., 2000). In addition, the half-life of ET-1 is only about 1 minute (Gasic, Wagner, et al., 1992), likely preventing effects at locations distant from the site of production. Although ET-1 is rapidly cleared, the resulting constrictive effects can last for hours to days (Asano, Ikegaki, et al., 1989; Vierhapper, Wagner, et al., 1990).

3.1.2 Endothelin receptors—Endothelin receptor A (ET_AR) and B (ET_BR) are G-protein coupled receptors that initiate intracellular signaling cascades upon activation (Bremnes, Paasche, et al., 2000). After ligand binding, Ca²⁺ signaling is increased in target cells via pathways involving phospholipase C stimulation (Resink, Scott-Burden, et al., 1988). ET-1-mediated Ca²⁺ influx can be long-lasting (>20 min) (Simonson & Dunn, 1990a; Simonson, Wann, et al., 1989) and so great that Ca²⁺ flowing through gap junctions is sufficient to initiate Ca²⁺ signaling in adjoining cells unbound by ET-1 (Simonson & Dunn, 1990b).

Many cell types express both ETRs, and the ratio of one to the other can vary (Kedzierski Yanagisawa, 2001). ET_ARs expressed on vascular smooth muscle cells mediate vasoconstriction. On the other hand, ET_BR, the sole ETR found on endothelial and renal collecting-duct cells (Johnstrom, Fryer, et al., 2005), function in ET clearance and in the release of vasodilators such as NO (Verhaar, Strachan, et al., 1998). As such, ET-1 injection into the vascular causes a brief vessel relaxation due to ET_BR activation. However this effect is quickly reversed by ET-1 binding to ET_AR, which reduces NO production in vascular smooth muscle cells and leads to the well-known constrictive effects of ET-1 in the vasculature.

3.1.3 The endothelin system in the heart—ET-1 can be produced by, and exert extravascular effects on, various cell types within the heart. Cardiomyocytes, endocardial/myocapillary endothelial cells, and cardiac fibroblasts can release ET-1, whereas both ET_AR and ET_BR are expressed on cardiomyocytes, fibroblasts, smooth muscle cells, and endocardial/myocapillary endothelial cells (Gray, Long, et al., 1998; Sakai, Miyauchi, et al.,

1996; Yanagisawa, Kurihara, et al., 1988). Activation of ET_AR signaling within cardiomyocytes can alter the force of myocardial contraction (inotropy) (K. Li, Stewart, et al., 1991; Mebazaa, Mayoux, et al., 1993), heart rate (chronotropy) (Kedzierski & Yanagisawa, 2001), hypertrophy (H. Ito, Hirata, et al., 1993), and cardiac rhythmicity (Russell & Molenaar, 2000). Approximately 90% of the ETR on cardiomyocytes are ET_AR (Fareh, Touyz, et al., 1996; Modesti, Vanni, et al., 1999), suggesting that the functional role of the ET system within the heart may be biased towards downstream effects of ET_AR. Thus ET production by multiple cell types in the heart combined with high ET_AR expression by cardiomyocytes could set the stage for ET-mediated cardiac dysfunction.

3.2 Endothelin-1 and cardiovascular disease

Endothelial dysfunction, the imbalanced release of vasoactive mediators, has been strongly associated with CV events. In healthy individuals ET and NO production are balanced to maintain normal vascular tone (Haynes & Webb, 1994). However, aberrant ET-1 mediated effects can lead to CVD, such as ischemia, hypertension, atherosclerosis, and cardiac dysfunction.

3.2.1 Ischemia and myocardial infarction—Ischemia, or inadequate supply of blood to a tissue or organ, can lead to MI when occurring within the heart. The ET system plays an important role in the consequences of ischemia and MI (Cernacek, Stewart, et al., 2003). Myocardial ischemia activates the ET system, upregulating ET-1 peptide levels and ETR transcription (Cernacek, Stewart, et al., 2003). Correspondingly, short-term inhibition of ET signaling in animal models immediately post-infarction improved survival rate and cardiac function. In humans, the levels of circulating ET-1 peptide were eight- and five-fold higher within a few hours of MI that did or did not cause reversible damage to the heart, respectively (Stewart, Kubac, et al., 1991).

3.2.2 Hypertension—The potential role of ET-1 in hypertension, an increase in mean arterial pressure (MAP; cardiac output multiplied by systemic vascular resistance), was postulated soon after its discovery. Bolus injection of ET-1 caused an immediate, but brief (minutes), increase in vessel diameter (C. E. Wright & Fozard, 1988) due to ET_BR-mediated NO release (Filep, Foldes-Filep, et al., 1993). This was quickly countered by ET activation of ET_ARs, which mediate strong and long-lasting vessel constriction. An increase in vascular resistance without a concurrent decrease in cardiac output can set the stage for hypertension by increasing MAP, and thus systemic BP (Bird, Waldron, et al., 1993; Gasic, Wagner, et al., 1992; Haynes, Clarke, et al., 1991; Haynes, Ferro, et al., 1996; McMahon, Palomo, et al., 1991; Veniant, Clozel, et al., 1994). Interestingly, human pulmonary hypertension is one of the few diseases in which ETR pharmacological agents have improved clinical outcomes.

3.2.3 Atherosclerosis—ET effects have also been linked to atherosclerosis (Ross, 1999), plaque formation in the arteries resulting from a process involving vascular injury, endothelial cell activation, and inflammation. Plaque disruption can release thrombi, leading to ischemic events after lodging in arteries. ET signaling through ET_AR can induce atherosclerosis via the release of proinflammatory mediators (Ruetten & Thiernemann,

1997) and the proliferation of fibroblasts and smooth muscle cells (Fujitani, Ninomiya, et al., 1995; MacNulty, Plevin, et al., 1990). In turn, ET-1 synthesis is upregulated in endothelial cells and macrophages upon exposure to pro-atherogenic factors (Boulanger, Tanner, et al., 1992; Martin-Nizard, Houssaini, et al., 1991). In addition, ET-1 concentrations are increased in the plaques of atherosclerosis in animal models (Mitani, Takimoto, et al., 2000) and ET-1 may promote atherosclerosis (Saleh, Boesen, et al., 2010) through its proliferative effects (Luscher, Seo, et al., 1993). There is also evidence that ET-1-mediated vessel constriction is enhanced in patients with atherosclerosis (Bohm, Johansson, et al., 2002), further exacerbating blood flow obstruction. Moreover, long-term ET_AR antagonism in humans can attenuate the progression of atherosclerotic coronary plaques (Yoon, Reriani, et al., 2013).

3.2.4 Cardiac hypertrophy—Cardiac hypertrophy, an increase in cardiomyocyte size, commonly occurs in response to hemodynamic stress, and has been related to conditions such as hypertension, HF, and ischemic disease (Frey, Katus, et al., 2004). Convincingly, the use of an ETR antagonist can attenuate cardiac hypertrophy in rats (Mulder, Richard, et al., 1997). In addition, ET-1 can initiate several pro-hypertrophic signaling pathways following activation of ET_AR in the heart. For example, ET-1 binding was found to alter Na⁺/H⁺ and Na⁺/Ca²⁺ ion exchangers in rat cardiomyocytes (Dulce, Hurtado, et al., 2006). ET_AR signaling can also activate phospholipase C and ERK1/2-mediated transcription of early genes related to hypertrophy (Marshall, Barrett, et al., 2010). Finally, ET may contribute to hypertrophy by mediating the vascular remodeling of resistance arteries (Amiri, Virdis, et al., 2004). (Mulder, Richard, et al., 1997)

3.2.5 Congestive heart failure—Nonphysiological cardiac hypertrophy is often a step on the path toward congestive heart failure (CHF). In support of a role for ET-1 in CHF, ET-1 peptide and ET_BR mRNA expression are increased in the cardiac tissues of patients with CHF (McMurray, Ray, et al., 1992; Zolk, Quatteck, et al., 1999). Concordantly, long-term treatment with an ET_AR antagonist can increase the survival rate of rats with CHF (Sakai, Miyauchi, et al., 1996). However, human clinical trials of ET_AR antagonists have repeatedly failed to improve the outcomes of patients with CHF (Anand, McMurray, et al., 2004; Battistini, Berthiaume, et al., 2006; Mylona & Cleland, 1999; O'Connor, Gattis, et al., 2003). Additional research into the mechanistic relationship between ET-1 and CHF may help provide an explanation for this apparent paradox.

3.2.6 Arrhythmia—Cardiac arrhythmia, or irregular heartbeat, can be benign or associated with a variety of adverse health outcomes, from dizziness to cardiac arrest. Ischemic events can cause arrhythmia, however evidence has pointed to a relationship between ET-1 and arrhythmia that does not require ischemia. Direct arrhythmogenic effects of ET-1 were reported in a study in which multiple concentrations of ET-1 (0.1 – 1 µg/kg) were administered into the aorta, near the coronary ostia of anesthetized rats (Yorikane & Koike, 1990). ET-1 administration had arrhythmogenic effects, even when ischemic effects were absent. The observation that ET-1-induced arrhythmias could occur without concomitant ischemia has since been corroborated by two additional studies in canines (Becker, Merkely, et al., 2000; Szabo, Geller, et al., 2000).

The mechanism behind direct ET-1-mediated arrhythmia may involve signal re-entry within the heart, ultimately driving action potential duration dispersion (early after depolarizations) and general electrophysiological heterogeneity (Duru, Barton, et al., 2001). This could be explained, at least in part, by the ability of ET-1 to influence Ca^{2+} handling and K^{+} currents. Along these lines, there is also evidence that prolonged conditions of elevated ET-1 may promote cardiac arrhythmia (T. Liu, Qin, et al., 2013). Sub-chronic (2 weeks) administration of ET-1 to rabbits resulted in altered cardiac action potential durations and membrane repolarization after hearts were isolated and perfused. Taken together, it appears that ET-1 directly mediates arrhythmia, although more work remains to better separate the direct arrhythmogenic actions of ET-1 from arrhythmia secondary to ischemia caused by ET-1.

3.3 Particulate matter-induced endothelin system activation

Animal studies first showed that inhalation of PM increased circulating ET-1 levels in 1998 (Bouthillier, Vincent, et al., 1998). Since then a relatively small number of studies have evaluated ET-1 production following PM exposure in humans. Most, but not all, of the human and animal studies have found that PM exposure increased ET-1 levels.

Three studies examined changes in circulating ET-1 peptide level after voluntary human exposure to relatively low concentrations of PM. In one study, ten subjects completed four cycles of 15 minutes rest and 15 minutes exercise while being exposed to filtered air (FA) or DE containing 100 g/m^3 PM (Lund, Lucero, et al., 2009). ET-1 peptide levels began to increase within 30 minutes post-exposure, and were significantly greater 24 hours post-exposure. A separate study also demonstrated an effect of DE on ET-1. Exposure to DE containing $200 \text{ }\mu\text{g/m}^3$ of PM increased circulating ET-1 levels three hours after 22 resting subjects completed a two hour-long exposure, whereas no changes were observed in subjects exposed to FA (Peretz, Sullivan, et al., 2008). In contrast, 13 healthy male volunteers exposed to either FA or dilute DE containing $300 \text{ }\mu\text{g/m}^3$ PM for one hour with 15-minute exercise/rest intervals found no increase in ET-1 levels over the next 24 hours (Langrish, Lundback, et al., 2009). However, an increased sensitivity to ET-1 was found after the researchers went on to inject the volunteers with ET-1 peptide at 5 pmol/min . ET-1 infusion caused vasoconstriction after DE inhalation, but not after FA. Moreover, administration of 10 nmol/min of an ET_A R antagonist lessened the DE-induced vasoconstriction, confirming the involvement of ET-1 signaling. Therefore, although it should be noted that exposure studies involving vehicle exhaust do include air pollutants other than PM, the above reports suggest that PM exposure in humans increases the levels of, and sensitivity to, ET-1 peptide.

Animal inhalation models have provided insight into transcriptional changes of the *Et-1* gene, *Edn1*, following PM exposure in the lung, aorta, and heart. One study found an increase of *Et-1* transcription in the lung (E. Thomson, Kumarathan, et al., 2005), and another in the heart (Ito, 2008 #31)(T. Ito, Suzuki, et al., 2008; Kodavanti, Thomas, et al., 2011; E. Thomson, Kumarathan, et al., 2005). In addition, two studies found that PM increased aortic *Et-1* expression (Campen, Lund, et al., 2010; Kodavanti, Thomas, et al., 2011). Overall, PM exposure may upregulate *Et-1* transcription in the CV system.

While transcript expression level changes can be informative, the levels of circulating ET-1 peptide are a more relevant measurement as ET system activation, as decreased ET-1

removal can modify functionality without changing transcription status (Johnstrom, Fryer, et al., 2005). Studies in which experimental animals were exposed to PM consistently reported increases in circulating plasma ET-1 concentrations, regardless of the animal model or PM concentration used (Bouthillier, Vincent, et al., 1998; Campen, McDonald, et al., 2006; Miyata, Hiraiwa, et al., 2013; E. Thomson, Kumarathasan, et al., 2005). Increases in ET-1 concentrations become even more striking when considering that they are likely caused by short-term and tissue-specific ET-1 changes.

Additional supportive evidence has come from epidemiological and occupational studies. A single research group, Calderón-Garcidueñas and colleagues, authored three epidemiological studies of ET-1 levels in relation to ambient PM air pollution. All of these studies compared responses in children from two cities in Mexico (one urban and one rural) with differing ambient PM_{2.5} and O₃ levels, and found that increased PM_{2.5} exposure was associated with increased levels of circulating ET-1 (Calderon-Garciduenas, Villarreal-Calderon, et al., 2008; Calderon-Garciduenas, Franco-Lira, et al., 2015; Calderon-Garciduenas, Vincent, et al., 2007).

An occupational study analyzed the association between the methylation status of *EDNI* and PM exposure (Tarantini, Bonzini, et al., 2013). DNA methylation is an epigenetic mechanism by which gene expression can be regulated (Jaenisch & Bird, 2003). Though neither PM₁₀ nor PM₁ exposure was associated with *EDNI* methylation, both were associated with an increase in thrombin potential (Tarantini, Bonzini, et al., 2013), an indicator of coagulation potential and thus a risk factor for disease (Siegemund, Petros, et al., 2004). Increased thrombin potential was, in turn, associated with decreased *EDNI* DNA methylation (Tarantini, Bonzini, et al., 2013). Interestingly, these researchers also found an association between zinc (Zn) exposure and *EDNI* hypomethylation. Zn is a common component of PM (Banerjee, 2003; Harrison & Yin, 2000; Schwar, Moorcroft, et al., 1988; Tong & Lam, 1998) and PM-associated Zn may mediate certain PM-induced cardiac effects (Kodavanti, Schladweiler, et al., 2002; Kodavanti, Schladweiler, et al., 2008; Wallenborn, Schladweiler, et al., 2009).

In addition, PM_{2.5} exposure upregulates ETR expression. Increased *Et_ar* mRNA expression has been reported in the heart, aorta, and lung after rodent exposure to PM (T. Ito, Suzuki, et al., 2008; Kodavanti, Thomas, et al., 2011; Upadhyay, Stoeger, et al., 2014). This idea is further supported by an *in vitro* study in which arteries from rat cerebrum were cultured in an aqueous suspension of 1 µg/ml PM_{2.5}. PM_{2.5} exposure significantly increased *Et_ar* and *Et_br* mRNA and protein expressions, and enhanced receptor-mediated contractions (Xiao, Wang, et al., 2015). While this concentration of PM_{2.5} is likely higher than would occur *in vivo*, this study demonstrates by proof-of-concept that direct tissue exposure to PM can increase ETR expression.

The few results finding no change or a decrease in ET-1 concentration after PM exposure could be due to several reasons, such as the type of PM air pollution, exposure length and concentration, and measurement timing. Nonetheless, when taken together, the human and animal studies strongly suggest that exposure to PM air pollution leads to systemic activation of the ET system. However, questions remain regarding ET effects on the heart.

4. Evidence of endothelin-1-mediated cardiac dysfunction following particulate matter exposure

Although the PM research community has begun to understand the vascular effects of ET-1 in CVD following PM exposure (Finch & Conklin, 2015), extravascular effects of ET-1 in this context have yet to be thoroughly investigated, particularly with regards to the direct effects of endothelins on cardiac tissue. Given that 1) PM exposure can increase ET-1 production, 2) PM exposure can result in cardiac dysfunction, and 3) ET-1 can function extravascularly to induce cardiac dysfunction, we propose that ET-1, as well as ET-1-induced secondary signaling agents, influence arrhythmia, inotropy, and chronotropy in the heart following PM exposure (Figure 1). Evidence integrating PM exposure, ET-1, and cardiac dysfunction into a single pathway is presented below.

A PubMed search was performed to identify publications that explored the role of ET-1 in mediating PM exposure-induced cardiac function¹. The limited body of literature that was identified and deemed relevant varied by type of model system, manner of ET-1 assessment (peptide vs. mRNA), cardiac endpoints considered, assessment timing, and exposure agent, concentration, and duration (Table 1). Eleven out of the 16 relevant publications described toxicological studies that used rats or mice as animal model systems, whereas the other five reported work with humans, and included two controlled human experiments, one epidemiological, and two occupational studies.

4.1 Epidemiologic evidence

The sole published epidemiological study investigating the relationships between PM_{2.5} exposure, ET-1, and cardiac function studied 28 healthy and non-smoking senior citizens (65 years of age or older) residing in nursing homes in Ontario, Canada (L. Liu, Ruddy, et al., 2009). Daily personal, indoor, and outdoor PM_{2.5} concentrations were monitored, cardiac function was assessed in terms of HR, and circulating ET-1 peptide levels were ascertained. The median personal and indoor daily PM_{2.5} exposure levels across the three facilities were 6–7 µg/m³, and the daily median outdoor concentration was 15.3 µg/m³. Indoor PM_{2.5} concentration was associated with both circulating ET-1 peptide and HR, and personal and outdoor PM_{2.5} concentrations were each associated with HR, supporting the hypothesis that a relationship exists between PM_{2.5} exposure, ET-1, and HR.

4.2 Toxicological and controlled human exposure evidence

4.2.1 Exposure to particulate matter alone—Intratracheal instillation approaches have also been used to better understand the relationships between PM-induced health effects and ET. Rodents exposed via intratracheal instillation to PM_{2.5} had increased circulating ET-1 levels in the heart and decreased HR (Upadhyay, Ganguly, et al., 2010). Instillation of 500 µg led to increased ET-1 three days later, and 1000 µg caused a similar increase within a single day. A second instillation exposure study subjected rats to a larger

¹The advanced PubMed search was performed on March 30, 2016 for “(particulate matter OR air pollution) AND (cardiac OR heart) AND (endothelin)”. Twenty-eight results were returned, one publication was added based on references from the returned articles, and 13 publications were deemed irrelevant and excluded. References are sorted by publication year.

dose (2000 $\mu\text{g PM}_{2.5}$) and left coronary artery occlusion. The authors found worsened ventricular arrhythmia as compared to animals subjected to occlusion but not exposed to PM, in addition to elevated circulating ET-1 levels and decreased HR (Kang, Li, et al., 2002).

Manufactured particles with physiochemical properties similar to naturally occurring particles could provide additional mechanistic insight. The intratracheal instillation of multi-walled carbon nanotubes, with or without ischemia/reperfusion injury, also altered the ET system and cardiac function (Thompson, Urankar, et al., 2014). Hearts isolated one day after whole-animal pulmonary instillation of 10 or 100 μg of multi-walled carbon nanotubes displayed an increased frequency of ventricular premature beats. In the same study, isolated hearts subjected to *ex vivo* ischemia and reperfusion displayed significantly increased ET-1 levels in the coronary effluent.

Inhalation studies of PM-mediated effects on ET-1 and cardiac dysfunction, likely more representative of human exposure, were first performed in rats. After a four hour exposure to high concentrations of EHC-93 (concentrated urban dust collected from Ottawa, Ontario; $\sim 50 \text{ mg/m}^3$) circulating ET-1 levels were increased (Vincent, Kumarathasan, et al., 2001). Interestingly, EHC-93 particles that lacked the soluble components (as compared to total EHC- caused a more rapid increase in ET-1 levels, within two hours post-exposure. However, there was no change in HR, the only measure of cardiac dysfunction collected in this study. A separate study found increased expression of *Et-1* and *Et_ar* mRNA in the hearts of rats that inhaled much lower concentrations ($1\text{--}2 \text{ }\mu\text{g/m}^3$) of concentrated ambient particles (CAPs; unaltered particles 0.1 to $2.5 \text{ }\mu\text{m}$ in diameter collected from the ambient air) 4.5 hours per day for four days, also without a parallel change in HR (T. Ito, Suzuki, et al., 2008).

Two papers by the same group evaluated the effects of inhaling $\sim 175 \text{ }\mu\text{g/m}^3$ UF carbon particles on HR and HRV in spontaneously hypertensive rats. In the first study, the authors demonstrated that inhalation of UF carbon particles caused an increase in HR and a decrease in HRV after exposure, which temporally correlated with significant induction of *Et-1* and *Et_ar* mRNA in the lung (Upadhyay, Stoeger, et al., 2008). Increases in *Et-1* mRNA were observed in the heart, but did not reach statistical significance. The second study by that group performed a similar experiment, but this time with aged (12–13 months) spontaneously hypertensive rats. Inhalation of UF carbon particles led to significantly increased HR, decreased HRV, and increased *Et-1* and *Et_ar* mRNA levels in the heart and lungs after exposure (Upadhyay, Stoeger, et al., 2014).

4.2.2 Exposure to particulate matter as a component of a mixture—Real-world ambient air pollution is a complex mixture that typically includes PM, gases, volatile and semivolatile compounds, and other pollutants. Although exposure to mixtures makes interpreting PM-specific effects more difficult, it can provide insight into the effects of PM in mixtures such as welding fumes, cigarette smoke (CS), and vehicle exhaust.

A study of $\text{PM}_{2.5}$, SO_2 , and NO_2 co-exposure also supported a role for PM in ET production and cardiac effects (Zhang, Ji, et al., 2015). Mice were exposed to two co-exposure doses for

28 days. The low dose was comprised of intranasal instillation of 1 mg/kg every other day alongside exposure to 0.5 mg/m³ SO₂ and 0.2 mg/m³ NO₂ for 6 hours per day, while the high dose followed a similar schedule but increased the instillation amount to 10 mg/kg and the SO₂ and NO₂ concentrations to 3.5 and 2 mg/m³, respectively. Both co-exposure dose resulted in increased HR, and the high dose also resulted in increased levels of ET-1 peptide and mRNA in the cardiac tissue.

Two occupational studies of welding fume exposure looked at effects of relatively high concentrations (3.5 and 4 mg/m³) over short timeframes (1 and 8 hours, respectively) (Jarvela, Kauppi, et al., 2013; Scharrer, Hessel, et al., 2007). Volunteers exposed for one hour displayed a very small (0.3 pg/mL), but statistically significant, decrease in circulating ET-1 levels and no changes in HR or HRV metrics five hours later (Scharrer, Hessel, et al., 2007). Steel welders evaluated before and after working a typical eight-hour day preceded by a two-day work break exhibited no change in circulating ET-1 or HRV (Jarvela, Kauppi, et al., 2013). Since subjects had been working as welders for an average of >13 years, it is possible that they become acclimated to the conditions and no longer experienced an activation of the ET system in response to welding fumes.

Exposure to CS caused alterations in the ET and cardiac related endpoints in three reports. In a controlled human exposure study performed over 20 years ago, an increase in circulating ET-1 was found within 10 minutes of smoking (Haak, Jungmann, et al., 1994). Not long after, it was reported that neonatal rats exposed to high concentrations of CS (1440 cigarettes over a 3 week period) displayed increased circulating ET-1 peptide levels (Zhu, Sun, et al., 1997). After subjecting the rodents to left coronary artery occlusion and reperfusion, the CS-exposed group also exhibited increased infarct size, an indicator of cardiac dysfunction, as compared to the unexposed group. More recently, rats exposed to 84 cigarettes over a 28 day period showed no change in circulating ET-1 peptide levels, though HR did decrease (Gentner & Weber, 2012).

Inhalation of gasoline and DE mixtures containing PM may also lead to changes in cardiac rhythm. One study showed rhythmicity changes and ET-1 peptide level increases at PM exposure concentrations as low as 60 µg/m³ (Campen, McDonald, et al., 2006). A particularly intriguing publication assessed CV function after simultaneous exposure of PM_{2.5} and O₃ to humans (Brook, Urch, et al., 2009). Though the authors found that an ET-1 antagonist abrogated exposure-induced BP elevations, the ability to attribute effects specifically to PM was limited, as effects of exposure to PM_{2.5} alone were not assessed.

The above research points to a potential role of ET-1 signaling in PM-mediated cardiac dysfunction. Specific evidence for and against ET-1 involvement in HR, HRV, arrhythmia, and MI is presented in Table 2, which summarizes the results of the studies in Table 1 by cardiac endpoint. Although Table 2 provides a different perspective on the current body of literature listed in Table 1, it does not examine the reasons why certain investigations reported different results, which could arise from differences in PM type, concentration, and exposure duration. In addition, most studies did not specifically evaluate ET-1 levels within the heart, making it difficult to interpret cardiac-specific ET-1 changes after PM exposure.

5. Endothelin-1 and the release of secondary cardiac-active mediators

ET-1 can promote the production and release of additional autocrine/paracrine signaling agents in the heart, which can exacerbate or antagonize ETR-mediated signaling effects (Jenkins, Cedars, et al., 2009; Noireaud & Andriantsitohaina, 2014). These agents include NO and prostaglandins such as prostacyclin (PGI₂) and thromboxane A₂ (TXA₂). PGI₂ is commonly regarded as a vasodilator and an inhibitor of clot formation, whereas TXA₂ is a vasoconstrictor with prothrombotic activity (Kawabe, Ushikubi, et al., 2010).

5.1 Cardiac-specific effects of nitric oxide

NO release is a downstream effect of ET_BR signaling (Verhaar, Strachan, et al., 1998). NO is generally regarded as a positive lusitropic agent, increasing myocardial relaxation during diastole (Rastaldo, Pagliaro, et al., 2007). NO effects on cardiac inotropy (the force of contraction) have been more puzzling. NO may increase inotropy via the nitrosylation of various cardiac proteins involved in excitation-contraction coupling and stretch-induced contractility (Noireaud & Andriantsitohaina, 2014). However, negative inotropic effects have been reported at higher NO concentrations (Brutsaert, 2003).

5.2 Cardiac-specific effects of prostaglandins

Prostaglandins are involved in various functions in the myocardium, including alterations in gene transcription, ion channel kinetics, and hemodynamics (Jenkins, Cedars, et al., 2009). Although prostaglandins can preserve normal heart function during physiological challenges, chronic or persistent prostaglandin release in the heart can adversely affect the conversion of an action potential to a contraction in a muscle fiber, known as excitation-contraction coupling (Neef & Maier, 2013), possibly leading to HF, arrhythmia, or even sudden cardiac death.

The first evidence that ET-1 caused prostaglandin release was published in 1988 (de Nucci, Thomas, et al., 1988). The perfusate of isolated lungs of guinea pigs and rats infused with ET contained the prostaglandins PGI₂ and TXA₂. In addition, PGI₂ was released when isolated rabbit hearts were perfused with ET-1 (Karwatowska-Prokopczuk & Wennmalm, 1990). ET-1 stimulation of rat vascular smooth muscle cells also increased thromboxane B₂ (a more stable and easily measurable metabolite of TXA₂ formed rapidly in the circulation) levels in cell culture media (Takayasu-Okishio, Terashita, et al., 1990). In addition, intravenous injection of ET-1 in guinea pigs caused an increase in MAP, bronchoconstriction, and thromboxane B₂ levels in bronchoalveolar lavage fluid (Lueddeckens, Bigl, et al., 1993). All of these changes were reduced or abrogated by eliminating the effects of TXA₂, while maintaining ET-1 signaling, demonstrating the specific effects of ET-1 mediated TXA₂ release. Prostaglandin synthesis is now a generally accepted downstream effect of ET-1 signaling.

Similar to the relationship between NO and ET-1, the effects of the prostaglandins PGI₂ and TXA₂ are generally thought to counterbalance each other, and when the regulation of either is altered, adverse health effects can occur. Interestingly, TXA₂ and PGI₂ concentrations in the local myocardium have been shown to correlate with early post-ischemic arrhythmias in

canines (Coker, Parratt, et al., 1981). In this report, subjects with elevated arrhythmia counts had elevated TXA2 and reduced PGI2 levels, whereas subjects with low arrhythmia counts had low TXA2 and elevated PGI2. Because of this, secondary autocrine/paracrine signaling responses during CV injury are thought to exacerbate the pro-arrhythmogenic effects of ET-1. This is exemplified during cardiac ischemia/reperfusion, a state in which ET-1 release from the heart increases (Brunner, du Toit, et al., 1992). If ET-1 initiates TXA2 release in cardiac tissue, the effects of ET-1 during adverse events like cardiac ischemia/reperfusion would be exacerbated.

5.3 Secondary release of prostaglandin and nitric oxide in the context of endothelin-1 and particulate matter exposure

Several lines of research have shown that PM exposure leads to cyclooxygenase (COX) activation and prostaglandin synthesis (Calderon-Garciduenas, Franco-Lira, et al., 2007; Maier, Alessandrini, et al., 2008), possibly due to ET-1 signaling, but the connection between ET-1 and secondary prostaglandin release is not yet clear. However, experiments employing COX inhibitors have demonstrated that prostaglandins mediate coronary vascular effects of ET-1 following pulmonary exposure to engineered nanomaterials. For example, pulmonary exposure to multi-walled carbon nanotubes in rats lead to increased release of cardiac ET-1 and depression of coronary flow during early reperfusion in isolated hearts subjected to ischemia/reperfusion one day after exposure, ultimately resulting in the expansion of MI (Thompson, Urankar, et al., 2014). Moreover, this study showed that coronary artery segments isolated from rats one day post-instillation generated increased force during ET-1 vasocontractions. The increased force was attenuated with COX inhibition, TXA2 synthetase inhibition, and TXA2 receptor antagonism, showing the functional effect was downstream of ET-1 signaling. Similarly, pulmonary instillation of carbon fullerenes caused rat coronary arteries isolated 24 hours after exposure to respond with increased force generation during ET-1 vasocontraction, which was attenuated with COX inhibition (Thompson, Urankar, et al., 2014). Although secondary ET-1 responses, likely mediated by TXA2, were not associated with ambient PM, it seems plausible that PM exposure from ambient air pollution sources could cause similar responses.

In summation, there is a large body of evidence demonstrating that ET-1 induces the release of secondary autocrine/paracrine mediators. As many of these secondary mediators can also influence cardiac function, they should be considered when investigating downstream effects of ET-1.

6. Endothelin receptor-targeted therapeutics and particulate matter

6.1 Endothelin receptor-targeted therapeutics

Understanding of the ET system quickly led to the development of ways in which the system could be manipulated. ET-1 antagonists were developed (Atkinson & Pelton, 1992; Bazil, Lappe, et al., 1992; Breu, Löffler, et al., 1993; Clozel, Breu, et al., 1993; Clozel, Breu, et al., 1994; Fukuroda, Nishikibe, et al., 1992; Ihara, Fukuroda, et al., 1991; Ihara, Noguchi, et al., 1992; Spinella, Malik, et al., 1991) almost immediately after the two mammalian ETRs were identified (Arai, Hori, et al., 1990; Sakurai, Yanagisawa, et al., 1990). Certain ET_AR

antagonists can reverse established ET-1-mediated constriction (Pierre & Davenport, 1999), suggesting that ET_AR antagonists can displace ET-1 or induce receptor internalization and degradation.

Unsurprisingly, it was thought that ETR antagonists could be employed as therapeutics for various ET-related health effects, and multiple clinical trials tested this hypothesis. Trials for pulmonary arterial hypertension (PAH) and scleroderma-related digital ulcers were promising, however several other trials found no difference in, or even a worsening of, health outcomes after treatment with ETR antagonists (Kohan, Cleland, et al., 2012). After extensive analysis of potential causes, it was concluded that poor study design and patient selection, combined with mechanistically-predictable side effects, likely skewed the results.

Foreseeable side effects of ETRs, mainly due to downstream ET_BR signaling, have caused several trials to be terminated prior to completion. The most problematic side effect has been fluid retention, which is associated with the use of virtually all known ETR antagonists (Battistini, Berthiaume, et al., 2006). Fluid retention has negatively impacted several clinical trials, such as one testing avosentan. Although avosentan treatment appeared to improve kidney function, it also caused a large increase in the number of patients with severe fluid retention and CHF, as compared to the patients receiving a placebo (Mann, Green, et al., 2010). This is not surprising as ET_BR signaling in the kidneys can regulate renal sodium and water transport (Kohan, 2006), allowing for the simultaneous improvement of kidney function and increase of fluid retention. A separate human trial that was performed during the above mentioned trial showed that fluid retention due to avosentan was dosage-dependent, and that avosentan could improve overt diabetic nephropathy at lower dosages than were being used (Wenzel, Littke, et al., 2009), underscoring the importance of dosage when designing informative clinical trials.

Functional events initiated by the two ETRs differ, suggesting that selectively antagonizing ET_AR to reduce pathophysiological effects while maintaining ET removal by ET_BR would be optimal. However, the first ETR antagonist to be approved for human treatment in the US and Europe was the dual receptor antagonist bosentan (Rubin & Roux, 2002). Five years later ambrisentan, a somewhat ET_AR-selective antagonist, entered the market. Ambrisentan was soon followed by sitaxsentan, a highly ET_AR-selective antagonist (Maguire & Davenport, 2014). In 2010, four patients receiving sitaxsentan died of liver failure and five others experienced severe hepatitis-like drug reactions, spurring its withdrawal from the market and the termination of ongoing trials (Galie, Hoeper, et al., 2011). Though the number affected was small, no deaths related to liver toxicity had been reported in the >90,000 patients treated with bosentan or ambrisentan. Though liver toxicity is unlikely related to receptor isoform specificity, these unfortunate occurrences further reduced interest in pursuing ETR antagonists as clinical therapeutics.

Poor study design may have also contributed to the failure of effective and relatively safe ETR antagonist therapeutics. A Phase III study of the relatively-selective ET_AR antagonist darusentan in patients with resistant hypertension found a significant reduction in ambulatory BP (Bakris, Lindholm, et al., 2010). However the trial was halted after finding no effect in the primary endpoint, sitting BP. Now, due to the selection of a suboptimal

health endpoint, research involving a drug demonstrated to be effective at reducing ambulatory BP in persons where other drugs have failed is unlikely to receive additional trials required for FDA approval.

Nevertheless, a recently developed ETR antagonist may have provided a reason to continue researching these types of therapeutics. Modifications to the nonselective receptor antagonist bosentan that decreased adverse side effects, increased tolerability, and improved efficacy led to the development of macitentan (Bolli, Boss, et al., 2012). Macitentan was approved by the FDA in 2013, and has since been generally accepted as the preeminent available ETR antagonist. This is due to several reasons, such as reductions in fluid retention, liver toxicity, and interactions with other drugs as compared to bosentan. In addition, macitentan is functional for a longer period of time after administration than bosentan. This increase has been credited to both the generation of a long-lasting and pharmacologically active (~48 hrs) metabolite of macitentan and that macitentan remains bound to ETRs for longer than bosentan, possibly due to binding site differences (Iglarz, Binkert, et al., 2008; Sidharta, van Giersbergen, et al., 2013; Sidharta, van Giersbergen, et al., 2011). Importantly, although macitentan was based on bosentan, it does display selectivity for ET_AR (Iglarz, Binkert, et al., 2008). These advantages position macitentan as both a useful PAH treatment option and a potential therapeutic for other ET-related pathologies.

6.2 Endothelin receptor antagonists and particulate matter

With the wide selection of ETR antagonists available and the involvement of ET production after PM exposure, it is surprising that so few studies have used ETR antagonists in the investigation of PM. Only 14 studies utilized ETR antagonism to better understand mechanisms following PM and exposure² (Table 3). The majority of these studies used CS or CS extract as the exposure agent evaluated very specific mechanistic endpoints, such as arterial contraction and changes in ET_BR expression levels (Aslani, Kesici, et al., 2015; T. Bhavsar, X. J. Liu, et al., 2008; T. M. Bhavsar, X. Liu, et al., 2008; Y. Chen, Chen, et al., 2010; Dadmanesh & Wright, 1997; Huang, Zhang, et al., 2013; Milara, Ortiz, et al., 2010; Milara, Gabarda, et al., 2012; Rahman, Elmi, et al., 2007; J. L. Wright, Sun, et al., 1999). ET-1 was demonstrated to mediate several effects of CS exposure, such as ET_BR expression and vessel constriction. However, no studies utilizing ETR antagonists have investigated the direct effect of ET-1 on PM-induced cardiac events, or looked at PM-related cardiac events in people already taking them for PAH or scleroderma-related digital ulcers.

Four studies using ETR antagonists have provided insight into the mechanisms of PM-mediated CVD. One exposed proatherosclerotic mice to gasoline engine exhaust containing 60 µg/m³ PM six hours a day for seven days, while also administering the ET_AR-specific antagonist BQ123 (Lund, Lucero, et al., 2009). The antagonist abrogated PM-exposure mediated increases in aortic *Et-1* mRNA, as well as transcription of matrix metalloproteinase 9, (Lin, Kakkar, et al., 2014) suggesting a role for ETR signaling in the

²An advanced PubMed search was performed on March 30, 2016 for “(particulate matter OR air pollution) AND (endothelin receptor antagonist OR bosentan OR ambrisentan OR avosentan OR darusentan OR macitentan OR sitaxsentan)”. Forteen results were returned, four of which were excluded for relevance. Four studies were added based on references from the returned articles and prior knowledge.

progression of atherosclerosis. In a second DE exposure study, ET_BR were reported to mediate the vasoconstriction of intraseptal coronary arteries after rats were exposed to 300 µg/m³ PM for 5 hours (Cherng, Campen, et al., 2009). The two remaining studies involved human subjects. One found that ETR mediated changes in forearm blood flow after 1 hour of exposure to dilute DE at 300 µg/m³ PM. The other human study concurrently exposed human volunteers to ~130 µg/m³ ambient PM_{2.5} and 120 ppb O₃ three times, each for a duration of two hours (Brook, Urch, et al., 2009). Pretreatment with a 250 mg dose of bosentan, a nonselective ETR antagonist, decreased BP and increased HR in response to PM_{2.5} and O₃. As such, ETRs appear to be involved in the ET-1 vascular response to PM. However, thus far pharmacological intervention studies targeting ET-1-mediated extravascular cardiac effects of PM exposure are lacking.

Regarding the studies in this section, it should be noted that pharmacological interventions, while valuable, are limited in their implications. For example, when administering ETR antagonists *in vivo*, the vascular and extravascular effects of ET-1, as well as effects on organ systems other than the heart, are difficult to tease apart. Although studies that incorporate the use of organ-specific ETR-deficient models may be more definitive in establishing the role of ET-1 in air pollution-induced cardiac health effects, the above intervention studies do suggest that ETR antagonists may reduce negative effects on the cardiovascular system after exposure to PM.

7. Conclusions and remaining questions

The individual bodies of literature regarding PM and ET are each vast, but the two fields have yet to be sufficiently integrated. In general terms, exposure to certain types of PM can lead to upregulation of ET-1 in various tissues (Finch & Conklin, 2015), and both ET-1 signaling and PM exposure can cause and exacerbate CVD (Franklin, Brook, et al., 2015). Very few studies have attempted to tie these findings together, and the majority of those that have focused on the vascular effects of ET-1, such as vessel constriction (Finch & Conklin, 2015). Though vascular effects of ET may be less complicated to observe and measure, effects of ET outside of the vasculature, such as direct cardiac effects, should not be overlooked. It will also be important to examine how ischemia resulting from ET-induced vasoconstriction of coronary vessels might exacerbate cardiac-specific effects such as inotropy, chronotropy, and arrhythmia, and vice versa. In other words, increased inotropy and chronotropy could further exacerbate ischemic injury in the heart by increasing blood demand when supply is reduced. Additional work using lessons learned from all relevant lines of research could be informative, potentially paving the path toward an improved understanding of PM-induced cardiac dysfunction. As such, several important unanswered research questions remain, a few of which we discuss below.

The mechanism by which PM exposure leads to ET upregulation within the heart has yet to be fully elucidated. As increases in ET-1 have been observed in the absence of pulmonary and systemic inflammation (Campen, McDonald, et al., 2006; Campen, Babu, et al., 2005; L. Liu, Ruddy, et al., 2009; Upadhyay, Stoeger, et al., 2008), mechanisms other than inflammation are likely to be involved in the activation of the ET system after PM exposure. Direct particle translocation could account for the rapid timing of effects observed after

exposure, however only a small amount of PM is likely able to leave the lungs (Brown, Zeman, et al., 2002; Burch, 2002; Mills, Tornqvist, et al., 2005; W. Moller, Felten, et al., 2008; US EPA, 2009; Wiebert, Sanchez-Crespo, Falk, et al., 2006; Wiebert, Sanchez-Crespo, Seitz, et al., 2006) and access the heart. Initiation via an autonomic pathway remains a plausible explanation, although evidence in support of this proposed mechanism is limited. Interestingly, PM exposure has been shown to increase norepinephrine concentrations in the lung (Chiarella, Soberanes, et al., 2014), brain (Sirivelu, MohanKumar, et al., 2006) and urine (Ying, Xu, et al., 2014). Independently, norepinephrine infusion can upregulate ET-1 expression in the heart (Kaddoura, Firth, et al., 1996). These separate lines of research suggest that PM exposure may activate an autonomic pathway leading to ET-1 production in the heart. This autonomic pathway could then be exacerbated by extravascular effects of ET-1. Once expression has increased in the heart, ET-1 can activate cardiac sympathetic afferent nerves and trigger a positive-feedback, sympathoexcitatory reflex (Fu, Guo, et al., 2010). In addition, ET-1 production in the brain following PM exposure (Guo, Zhu, et al., 2012; Ohno, Tanaka, et al., 2004; E. M. Thomson, Kumarathasan, et al., 2007) can enhance the cardiac sympathetic afferent reflex (A. D. Chen, Xiong, et al., 2012). In a similar vein, ET-1 produced in the lungs following PM exposure (Upadhyay, Stoeger, et al., 2014; Upadhyay, Stoeger, et al., 2008) could sensitize and/or activate airway sensory afferent nerves, as was demonstrated in peripheral C-fibers (Namer, Hilliges, et al., 2008). As such, ET-1 upregulation in the heart following PM exposure could be mediated by norepinephrine release and enhanced by ET-1-mediated nerve activation in the lungs, heart, and brain.

ET produced by cardiac tissue after PM exposure could differ in timing or magnitude from changes in circulating or lung ET-1. Of the five studies that looked at ET-1 peptide or mRNA changes specifically within the heart after PM exposure, four studies measured changes in *Et-1* mRNA levels, one assessed ET-1 peptide levels, and one paper evaluated both. Three reports found increased *Et-1* mRNA levels (H. Ito, Hirata, et al., 1993; Upadhyay, Ganguly, et al., 2010), whereas one found no change (Upadhyay, Stoeger, et al., 2008). However, as increased transcription may not reflect the rate of biologically active ET-1 peptide synthesis or account for peptide sequestration efficiency, changes in transcription may not reflect local ET-1 peptide level changes within heart tissue. The two studies that directly evaluated ET-1 peptide levels in the heart both found significant increases (Upadhyay, Ganguly, et al., 2010; Zhang, Ji, et al., 2015), providing sufficient rationale for additional studies to confirm this finding. Cardiac tissue from model systems could be used to provide further evidence of PM-mediated increases in ET-1 peptide levels, as well as to determine which cell types produce or are affected by ET-1 (e.g., cardiomyocytes vs. endocardial/myocardial endothelial cells). If PM increases ET-1 peptide levels in exposed animals, it would be useful to also confirm this finding in humans. Outside of obtaining excess material from myocardial biopsies in humans, research may be limited to animal studies and human *in vitro* studies in order to correlate cardiac ET-1 changes with PM exposure and adverse cardiac events in humans, which could still potentially provide convincing evidence that PM leads to ET production in the heart.

While confirming that ET-1 peptide production in the heart is increased after PM exposure would strongly suggest that ET-1 may mediate cardiac dysfunction in this context, mechanistic studies are needed to verify this hypothesis and more clearly describe the types

of cardiac dysfunction resulting from PM exposure. This is possible, as an array of ETR antagonists and agonists with varying receptor specificities are available to confirm that ET contributes to PM-induced CVD. Use of ETR agonists and antagonists in animal models to attenuate and exacerbate, respectively, adverse CV effects after PM exposure could provide clear mechanistic evidence of the involvement of ET. Isolated perfused heart preparations could be utilized to extricate extravascular from vascular ET effects on cardiac function. Alternatively, retrospective human epidemiological studies comparing CV outcomes in patients that have or have not taken ETR therapeutics could present additional insight on the role of ET-1 signaling in humans.

Additional research is needed to better understand the impact of ET-mediated secondary release of autocrine/paracrine agents on the development and progression of CVD following PM exposure, specifically within the heart. Physiologically, endocardial/myocardial endothelial cells are co-located so that ET may preferentially influence cardiomyocyte function (Figure 1). Because of this, it would be interesting to further tease apart direct ET-1 effects from those of the numerous secondary autocrine/paracrine agents within the heart after various PM exposure scenarios, possibly using cell co-culture systems. In turn, characterizing the cardiac-specific effects of secondary ET-1 signaling from the vascular-specific effects within the heart could provide an initial mechanistic understanding of the cascade of events following ET-1 upregulation.

Here we have proposed and supported the idea that altered autocrine/paracrine signaling directly influences cardiac function and can lead to certain cardiac health effects of PM exposure. ET-1 was selected as a case study for this hypothesis, as it may be a central mediator involved in the propagation of CV health consequences initiated by pulmonary exposure to PM. Alterations in other autocrine/paracrine signaling agents, such as TXA₂, PGI₂, and NO, also are logical candidates, but are each linked to ET-1. Given the population-wide impacts of PM, improving insight into how ET signaling in the heart can be influenced by PM exposure would likely positively impact treatment approaches for CV disease.

Acknowledgments

We thank Dr. Erin Hines, Dr. Urmila Kodavanti, Dr. Steven Dutton, and Dr. John Vandenberg for helpful comments on the manuscript and Molly Windsor for assistance with the figure.

Funding Sources

This research was supported in part by appointments to the Research Participation Program for the U.S. EPA, Office of Research and Development, administered by Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and EPA.

Abbreviations

ACSCPII	American Cancer Society Cancer Prevention II
ANS	autonomic nervous system
BP	blood pressure

CV	cardiovascular
CVD	cardiovascular disease
CS	cigarette smoke
CAP	concentrated ambient particle
CHF	congestive heart failure
COX	cyclooxygenase
DE	diesel exhaust
eNOS	endothelial NO synthase
ET	endothelin
ETR	endothelin receptor
ET_AR	endothelin receptor A
ET_BR	endothelin receptor B
EPA	Environmental Protection Agency
FA	filtered air
HF	heart failure
HR	heart rate
HRV	heart rate variability
MAP	mean arterial pressure
MESA	Multi-Ethnic Study of Atherosclerosis
MI	myocardial infarction
NO	nitric oxide
NO₂	nitrogen dioxide
O₃	ozone
PM	particulate matter
PGI₂	prostacyclin
PAH	pulmonary arterial hypertension
SHR	spontaneously hypertensive rat
SO₂	sulfur dioxide
TXA₂	thromboxane A ₂

TRPA1	transient receptor potential cation channel member A1
UFP	ultrafine particle
US	United States
Zn	zinc

References

- Adar SD, Sheppard L, Vedal S, Polak JF, Sampson PD, Diez Roux AV, Budoff M, Jacobs DR, Jr., Barr RG, Watson K, & Kaufman JD (2013). Fine particulate air pollution and the progression of carotid intima-medial thickness: a prospective cohort study from the multi-ethnic study of atherosclerosis and air pollution. *PLoS Med*, 10, e1001430. [PubMed: 23637576]
- Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, & Schiffrin EL (2004). Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. *Circulation*, 110, 2233–2240. [PubMed: 15466627]
- Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF, & investigators, E. (2004). Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. *Lancet*, 364, 347–354. [PubMed: 15276394]
- Arai H, Hori S, Aramori I, Ohkubo H, & Nakanishi S (1990). Cloning and expression of a cDNA encoding an endothelin receptor. *Nature*, 348, 730–732. [PubMed: 2175396]
- Asano T, Ikegaki I, Suzuki Y, Satoh S, & Shibuya M (1989). Endothelin and the production of cerebral vasospasm in dogs. *Biochem Biophys Res Commun*, 159, 1345–1351. [PubMed: 2649099]
- Aslani H, Kesici H, Karaca ZI, Ozyurt B, Tas U, Ekici F, Erdogan H, Gevrek F, & Cayli S (2015). Beneficial effects of melatonin and BQ-123 on the rat testis damage caused by cigarette smoke. *Turk J Med Sci*, 45, 11–17. [PubMed: 25790524]
- Atkinson RA, & Pelton JT (1992). Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist. *FEBS Lett*, 296, 1–6. [PubMed: 1309703]
- Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, & Weber M (2010). Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. *Hypertension*, 56, 824–830. [PubMed: 20921430]
- Banerjee AD (2003). Heavy metal levels and solid phase speciation in street dusts of Delhi, India. *Environ Pollut*, 123, 95–105. [PubMed: 12663209]
- Battistini B, Berthiaume N, Kelland NF, Webb DJ, & Kohan DE (2006). Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. *Exp Biol Med* (Maywood), 231, 653–695. [PubMed: 16740981]
- Bazil MK, Lappe RW, & Webb RL (1992). Pharmacologic characterization of an endothelin A (ETA) receptor antagonist in conscious rats. *J Cardiovasc Pharmacol*, 20, 940–948. [PubMed: 1282597]
- Becker R, Merkely B, Bauer A, Geller L, Fazekas L, Freigang KD, Voss F, Senges JC, Kuebler W, & Schoels W (2000). Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three-dimensional mapping. *Cardiovasc Res*, 45, 310–320. [PubMed: 10728351]
- Bell ML, Davis DL, & Fletcher T (2004). A retrospective assessment of mortality from the London smog episode of 1952: the role of influenza and pollution. *Environ Health Perspect*, 112, 6–8. [PubMed: 14698923]
- Bellinger DL, & Lorton D (2014). Autonomic regulation of cellular immune function. *Auton Neurosci*, 182, 15–41. [PubMed: 24685093]
- Bhavsar T, Liu XJ, Patel H, Stephani R, & Cantor JO (2008). Preferential recruitment of neutrophils by endothelin-1 in acute lung inflammation induced by lipopolysaccharide or cigarette smoke. *Int J Chron Obstruct Pulmon Dis*, 3, 477–481. [PubMed: 18990977]
- Bhavsar TM, Liu X, Cerreta JM, Liu M, & Cantor JO (2008). Endothelin-1 potentiates smoke-induced acute lung inflammation. *Exp Lung Res*, 34, 707–716. [PubMed: 19085567]

- Bird JE, Waldron TL, Dorso CR, & Asaad MM (1993). Effects of the endothelin (ET) receptor antagonist BQ 123 on initial and delayed vascular responses induced by ET-1 in conscious, normotensive rats. *J Cardiovasc Pharmacol*, 22, 69–73. [PubMed: 7690099]
- Bohm F, Johansson BL, Hedin U, Alving K, & Pernow J (2002). Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. *Atherosclerosis*, 160, 215–222. [PubMed: 11755940]
- Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, & Weller T (2012). The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. *J Med Chem*, 55, 7849–7861. [PubMed: 22862294]
- Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, & Luscher TF (1992). Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. *Circ Res*, 70, 1191–1197. [PubMed: 1315634]
- Bouthillier L, Vincent R, Goegan P, Adamson IY, Bjarnason S, Stewart M, Guenette J, Potvin M, & Kumarathasan P (1998). Acute effects of inhaled urban particles and ozone: lung morphology, macrophage activity, and plasma endothelin-1. *Am J Pathol*, 153, 1873–1884. [PubMed: 9846977]
- Bremnes T, Paasche JD, Mehluum A, Sandberg C, Bremnes B, & Attramadal H (2000). Regulation and intracellular trafficking pathways of the endothelin receptors. *J Biol Chem*, 275, 17596–17604. [PubMed: 10747877]
- Breu V, Loffler BM, & Clozel M (1993). In vitro characterization of Ro 46–2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. *FEBS Lett*, 334, 210–214. [PubMed: 8224248]
- Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, Luepker R, Mittleman M, Samet J, Smith SC, Jr., Tager I, Expert Panel on, P., & Prevention Science of the American Heart, A. (2004). Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. *Circulation*, 109, 2655–2671. [PubMed: 15173049]
- Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC, Jr., Whitsel L, & Kaufman JD (2010). Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. *Circulation*, 121, 2331–2378. [PubMed: 20458016]
- Brook RD, Bard RL, Morishita M, Dvonch JT, Wang L, Yang HY, Spino C, Mukherjee B, Kaplan MJ, Yalavarthi S, Oral EA, Ajluni N, Sun Q, Brook JR, Harkema J, & Rajagopalan S (2014). Hemodynamic, autonomic, and vascular effects of exposure to coarse particulate matter air pollution from a rural location. *Environ Health Perspect*, 122, 624–630. [PubMed: 24618231]
- Brook RD, Urch B, Dvonch JT, Bard RL, Speck M, Keeler G, Morishita M, Marsik FJ, Kamal AS, Kaciroti N, Harkema J, Corey P, Silverman F, Gold DR, Wellenius G, Mittleman MA, Rajagopalan S, & Brook JR (2009). Insights into the mechanisms and mediators of the effects of air pollution exposure on blood pressure and vascular function in healthy humans. *Hypertension*, 54, 659–667. [PubMed: 19620518]
- Brown JS, Zeman KL, & Bennett WD (2002). Ultrafine particle deposition and clearance in the healthy and obstructed lung. *Am J Respir Crit Care Med*, 166, 1240–1247. [PubMed: 12403694]
- Brown JS, Gordon T, Price O, & Asgharian B (2013). Thoracic and respirable particle definitions for human health risk assessment. *Part Fibre Toxicol*, 10, 12. [PubMed: 23575443]
- Brunner F, du Toit EF, & Opie LH (1992). Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. *J Mol Cell Cardiol*, 24, 1291–1305. [PubMed: 1479622]
- Brutsaert DL (2003). Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. *Physiol Rev*, 83, 59–115. [PubMed: 12506127]
- Burch WM (2002). Passage of inhaled particles into the blood circulation in humans. *Circulation*, 106, e141–142; author reply e141–142. [PubMed: 12427664]
- Calderon-Garciduenas L, Franco-Lira M, Torres-Jardon R, Henriquez-Roldan C, Barragan-Mejia G, Valencia-Salazar G, Gonzalez-Maciel A, Reynoso-Robles R, Villarreal-Calderon R, & Reed W

- (2007). Pediatric respiratory and systemic effects of chronic air pollution exposure: nose, lung, heart, and brain pathology. *Toxicol Pathol*, 35, 154–162. [PubMed: 17325984]
- Calderon-Garciduenas L, Villarreal-Calderon R, Valencia-Salazar G, Henriquez-Roldan C, Gutierrez-Castrellon P, Torres-Jardon R, Osnaya-Brizuela N, Romero L, Torres-Jardon R, Solt A, & Reed W (2008). Systemic inflammation, endothelial dysfunction, and activation in clinically healthy children exposed to air pollutants. *Inhal Toxicol*, 20, 499–506. [PubMed: 18368620]
- Calderon-Garciduenas L, Franco-Lira M, D'Angiulli A, Rodriguez-Diaz J, Blaurock-Busch E, Busch Y, Chao CK, Thompson C, Mukherjee PS, Torres-Jardon R, & Perry G (2015). Mexico City normal weight children exposed to high concentrations of ambient PM_{2.5} show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. *Environ Res*, 140, 579–592. [PubMed: 26037109]
- Calderon-Garciduenas L, Vincent R, Mora-Tiscareno A, Franco-Lira M, Henriquez-Roldan C, Barragan-Mejia G, Garrido-Garcia L, Camacho-Reyes L, Valencia-Salazar G, Paredes R, Romero L, Osnaya H, Villarreal-Calderon R, Torres-Jardon R, Hazucha MJ, & Reed W (2007). Elevated plasma endothelin-1 and pulmonary arterial pressure in children exposed to air pollution. *Environ Health Perspect*, 115, 1248–1253. [PubMed: 17687455]
- Campen MJ, McDonald JD, Reed MD, & Seagrave J (2006). Fresh gasoline emissions, not paved road dust, alter cardiac repolarization in ApoE^{−/−} mice. *Cardiovasc Toxicol*, 6, 199–210. [PubMed: 17347530]
- Campen MJ, Babu NS, Helms GA, Pett S, Wernly J, Mehran R, & McDonald JD (2005). Nonparticulate components of diesel exhaust promote constriction in coronary arteries from ApoE^{−/−} mice. *Toxicol Sci*, 88, 95–102. [PubMed: 16093524]
- Campen MJ, Lund AK, Doyle-Eisele ML, McDonald JD, Knuckles TL, Rohr AC, Knipping EM, & Mauderly JL (2010). A comparison of vascular effects from complex and individual air pollutants indicates a role for monoxide gases and volatile hydrocarbons. *Environ Health Perspect*, 118, 921–927. [PubMed: 20197249]
- CDC. (2015). Underlying Cause of Death 1999–2013 on CDC WONDER Online Database, released 2015 2013.
- Cernacek P, Stewart DJ, Monge JC, & Rouleau JL (2003). The endothelin system and its role in acute myocardial infarction. *Can J Physiol Pharmacol*, 81, 598–606. [PubMed: 12839271]
- Chen AD, Xiong XQ, Gan XB, Zhang F, Zhou YB, Gao XY, & Han Y (2012). Endothelin-1 in paraventricular nucleus modulates cardiac sympathetic afferent reflex and sympathetic activity in rats. *PLoS One*, 7, e40748. [PubMed: 22815806]
- Chen R, Kan H, Chen B, Huang W, Bai Z, Song G, Pan G, & Group CC (2012). Association of particulate air pollution with daily mortality: the China Air Pollution and Health Effects Study. *Am J Epidemiol*, 175, 1173–1181. [PubMed: 22510278]
- Chen Y, Chen P, Masayuki H, Peng H, Yunden D, & Keishi K (2010). [The mechanism and pulmonary-protective effects of endothelin-1 receptor antagonist in chronic obstructive pulmonary diseases rat model]. *Zhonghua Nei Ke Za Zhi*, 49, 380–384. [PubMed: 20646409]
- Cherng TW, Campen MJ, Knuckles TL, Gonzalez Bosc L, & Kanagy NL (2009). Impairment of coronary endothelial cell ET(B) receptor function after short-term inhalation exposure to whole diesel emissions. *Am J Physiol Regul Integr Comp Physiol*, 297, R640–647. [PubMed: 19535675]
- Chiarella SE, Soberanes S, Urlich D, Morales-Nebreda L, Nigdelioglu R, Green D, Young JB, Gonzalez A, Rosario C, & Misharin AV (2014). β 2-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. *J Clin Invest*, 124, 2935–2946. [PubMed: 24865431]
- Cho S, & Atwood JE (2002). Peripheral edema. *Am J Med*, 113, 580–586. [PubMed: 12459405]
- Clouthier DE, Williams SC, Yanagisawa H, Wieduwilt M, Richardson JA, & Yanagisawa M (2000). Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. *Dev Biol*, 217, 10–24. [PubMed: 10625532]
- Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Loffler BM, Muller M, Neidhart W, & et al. (1993). Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. *Nature*, 365, 759–761. [PubMed: 8413655]

- Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W, & et al. (1994). Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. *J Pharmacol Exp Ther*, 270, 228–235. [PubMed: 8035319]
- Coker SJ, Parratt JR, Ledingham IM, & Zeitlin IJ (1981). Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. *Nature*, 291, 323–324. [PubMed: 6894485]
- Crouse DL, Peters PA, van Donkelaar A, Goldberg MS, Villeneuve PJ, Brion O, Khan S, Atari DO, Jerrett M, Pope CA, Brauer M, Brook JR, Martin RV, Stieb D, & Burnett RT (2012). Risk of nonaccidental and cardiovascular mortality in relation to long-term exposure to low concentrations of fine particulate matter: a Canadian national-level cohort study. *Environ Health Perspect*, 120, 708–714. [PubMed: 22313724]
- Dadmanesh F, & Wright JL (1997). Endothelin-A receptor antagonist BQ-610 blocks cigarette smoke-induced mitogenesis in rat airways and vessels. *Am J Physiol*, 272, L614–618. [PubMed: 9142933]
- de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, & Vane JR (1988). Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. *Proc Natl Acad Sci U S A*, 85, 9797–9800. [PubMed: 3059352]
- Delfino RJ, Staimer N, Tjoa T, Polidori A, Arhami M, Gillen DL, Kleinman MT, Vaziri ND, Longhurst J, Zaldivar F, & Sioutas C (2008). Circulating biomarkers of inflammation, antioxidant activity, and platelet activation are associated with primary combustion aerosols in subjects with coronary artery disease. *Environ Health Perspect*, 116, 898–906. [PubMed: 18629312]
- Dockery DW, Pope CA, 3rd, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG, Jr., & Speizer FE (1993). An association between air pollution and mortality in six U.S. cities. *N Engl J Med*, 329, 1753–1759. [PubMed: 8179653]
- Dominici F, Peng RD, Bell ML, Pham L, McDermott A, Zeger SL, & Samet JM (2006). Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. *JAMA*, 295, 1127–1134. [PubMed: 16522832]
- Dulce RA, Hurtado C, Ennis IL, Garcarena CD, Alvarez MC, Caldiz C, Pierce GN, Portiansky EL, de Cingolani GEC, & de Hurtado MCC (2006). Endothelin-1 induced hypertrophic effect in neonatal rat cardiomyocytes: Involvement of Na⁺/H⁺ and Na⁺/Ca²⁺ exchangers. *J Mol Cell Cardiol*, 41, 807–815. [PubMed: 16859700]
- Duru F, Barton M, Luscher TF, & Candinas R (2001). Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? *Cardiovasc Res*, 49, 272–280. [PubMed: 11164837]
- Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, & Fauci AS (1990). Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. *J Exp Med*, 172, 1741–1748. [PubMed: 1701822]
- Fareh J, Touyz RM, Schiffrin EL, & Thibault G (1996). Endothelin-1 and angiotensin II receptors in cells from rat hypertrophied heart. Receptor regulation and intracellular Ca²⁺ modulation. *Circ Res*, 78, 302–311. [PubMed: 8575074]
- Filep JG, Foldes-Filep E, Rousseau A, Sirois P, & Fournier A (1993). Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat. *Br J Pharmacol*, 110, 1213–1221. [PubMed: 8298811]
- Finch J, & Conklin DJ (2015). Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System. *Cardiovasc Toxicol*
- Forsythe P (2015). The Parasympathetic Nervous System as a Regulator of Mast Cell Function. In *Mast Cells* (pp. 141–154): Springer.
- Franklin BA, Brook R, & Arden Pope C, 3rd. (2015). Air pollution and cardiovascular disease. *Curr Probl Cardiol*, 40, 207–238. [PubMed: 25882781]
- Frey N, Katus HA, Olson EN, & Hill JA (2004). Hypertrophy of the heart: a new therapeutic target? *Circulation*, 109, 1580–1589. [PubMed: 15066961]
- Fu LW, Guo ZL, & Longhurst JC (2010). Endogenous endothelin stimulates cardiac sympathetic afferents during ischaemia. *J Physiol*, 588, 2473–2486. [PubMed: 20442267]

- Fujii T, Hayashi S, Hogg JC, Mukae H, Suwa T, Goto Y, Vincent R, & van Eeden SF (2002). Interaction of alveolar macrophages and airway epithelial cells following exposure to particulate matter produces mediators that stimulate the bone marrow. *Am J Respir Cell Mol Biol*, 27, 34–41. [PubMed: 12091243]
- Fujitani Y, Ninomiya H, Okada T, Urade Y, & Masaki T (1995). Suppression of endothelin-1-induced mitogenic responses of human aortic smooth muscle cells by interleukin-1 beta. *J Clin Invest*, 95, 2474–2482. [PubMed: 7769093]
- Fukuroda T, Nishikibe M, Ohta Y, Ihara M, Yano M, Ishikawa K, Fukami T, & Ikemoto F (1992). Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist, BQ-153. *Life Sci*, 50, PL107–112. [PubMed: 1313516]
- Furuyama A, Kanno S, Kobayashi T, & Hirano S (2009). Extrapulmonary translocation of intratracheally instilled fine and ultrafine particles via direct and alveolar macrophage-associated routes. *Arch Toxicol*, 83, 429–437. [PubMed: 18953527]
- Galie N, Hoeper MM, Gibbs JS, & Simonneau G (2011). Liver toxicity of sitaxentan in pulmonary arterial hypertension. *Eur Respir J*, 37, 475–476. [PubMed: 21282816]
- Gasic S, Wagner OF, Vierhapper H, Nowotny P, & Waldhausl W (1992). Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. *J Cardiovasc Pharmacol*, 19, 176–180. [PubMed: 1376785]
- Gentner NJ, & Weber LP (2012). Secondhand tobacco smoke, arterial stiffness, and altered circadian blood pressure patterns are associated with lung inflammation and oxidative stress in rats. *Am J Physiol Heart Circ Physiol*, 302, H818–825. [PubMed: 22140051]
- Ghelfi E, Rhoden CR, Wellenius GA, Lawrence J, & Gonzalez-Flecha B (2008). Cardiac oxidative stress and electrophysiological changes in rats exposed to concentrated ambient particles are mediated by TRP-dependent pulmonary reflexes. *Toxicol Sci*, 102, 328–336. [PubMed: 18184637]
- Gray MO, Long CS, Kalinyak JE, Li HT, & Karliner JS (1998). Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. *Cardiovasc Res*, 40, 352–363. [PubMed: 9893729]
- Guo L, Zhu N, Guo Z, Li GK, Chen C, Sang N, & Yao QC (2012). Particulate matter (PM10) exposure induces endothelial dysfunction and inflammation in rat brain. *J Hazard Mater*, 213–214, 28–37.
- Haak T, Jungmann E, Kasper-Dahm G, Ehrlich S, & Usadel KH (1994). Elevated endothelin 1 levels in critical illness. *Clin Investig*, 72, 214.
- Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, & Buhler FR (1990). Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. *Cell Regul*, 1, 649–659. [PubMed: 2078571]
- Hao M, Comier S, Wang M, Lee JJ, & Nel A (2003). Diesel exhaust particles exert acute effects on airway inflammation and function in murine allergen provocation models. *J Allergy Clin Immunol*, 112, 905–914. [PubMed: 14610479]
- Harrison RM, & Yin J (2000). Particulate matter in the atmosphere: which particle properties are important for its effects on health? *Sci Total Environ*, 249, 85–101. [PubMed: 10813449]
- Haynes WG, & Webb DJ (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. *Lancet*, 344, 852–854. [PubMed: 7916401]
- Haynes WG, Clarke JG, Cockcroft JR, & Webb DJ (1991). Pharmacology of endothelin-1 in vivo in humans. *J Cardiovasc Pharmacol*, 17 Suppl 7, S284–286. [PubMed: 1725356]
- Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, & Webb DJ (1996). Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. *Circulation*, 93, 1860–1870. [PubMed: 8635265]
- Hazari MS, Haykal-Coates N, Winsett DW, Krantz QT, King C, Costa DL, & Farraj AK (2011). TRPA1 and sympathetic activation contribute to increased risk of triggered cardiac arrhythmias in hypertensive rats exposed to diesel exhaust. *Environ Health Perspect*, 119, 951–957. [PubMed: 21377951]
- Hiraiwa K, & van Eeden SF (2013). Contribution of lung macrophages to the inflammatory responses induced by exposure to air pollutants. *Mediators Inflamm*, 2013, 619523. [PubMed: 24058272]

- Hiura TS, Kaszubowski MP, Li N, & Nel AE (1999). Chemicals in diesel exhaust particles generate reactive oxygen radicals and induce apoptosis in macrophages. *J Immunol*, 163, 5582–5591. [PubMed: 10553087]
- Hoek G, Krishnan RM, Beelen R, Peters A, Ostro B, Brunekreef B, & Kaufman JD (2013). Long-term air pollution exposure and cardio- respiratory mortality: a review. *Environ Health*, 12, 43. [PubMed: 23714370]
- Huang LH, Zhang PA, He JY, Liu J, & Cao YX (2013). DMSO-soluble cigarette smoke particles alter the expression of endothelin B receptor in rat coronary artery. *J Vasc Res*, 50, 238–248. [PubMed: 23712000]
- Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, & Clozel M (2008). Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. *J Pharmacol Exp Ther*, 327, 736–745. [PubMed: 18780830]
- Ihara M, Fukuroda T, Saeki T, Nishikibe M, Kojiri K, Suda H, & Yano M (1991). An endothelin receptor (ETA) antagonist isolated from *Streptomyces misakiensis*. *Biochem Biophys Res Commun*, 178, 132–137. [PubMed: 1648907]
- Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, & Yano M (1992). Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. *Life Sci*, 50, 247–255. [PubMed: 1310132]
- Inoue A, Yanagisawa M, Takawa Y, Mitsui Y, Kobayashi M, & Masaki T (1989). The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. *J Biol Chem*, 264, 14954–14959. [PubMed: 2670930]
- Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, & Masaki T (1989). The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci U S A*, 86, 2863–2867. [PubMed: 2649896]
- Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, & Hiroe M (1993). Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. *J Clin Invest*, 92, 398–403. [PubMed: 8326007]
- Ito T, Suzuki T, Tamura K, Nezu T, Honda K, & Kobayashi T (2008). Examination of mRNA expression in rat hearts and lungs for analysis of effects of exposure to concentrated ambient particles on cardiovascular function. *Toxicology*, 243, 271–283. [PubMed: 18077076]
- Jaenisch R, & Bird A (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet*, 33 Suppl, 245–254. [PubMed: 12610534]
- Jarvela M, Kauppi P, Tuomi T, Luukkonen R, Lindholm H, Nieminen R, Moilanen E, & Hannu T (2013). Inflammatory response to acute exposure to welding fumes during the working day. *Int J Occup Med Environ Health*, 26, 220–229. [PubMed: 23690265]
- Jeng HA (2010). Chemical composition of ambient particulate matter and redox activity. *Environ Monit Assess*, 169, 597–606.
- Jenkins CM, Cedars A, & Gross RW (2009). Eicosanoid signalling pathways in the heart. *Cardiovasc Res*, 82, 240–249. [PubMed: 19074824]
- Jerrett M, Burnett RT, Beckerman BS, Turner MC, Krewski D, Thurston G, Martin RV, van Donkelaar A, Hughes E, Shi Y, Gapstur SM, Thun MJ, & Pope CA, 3rd. (2013). Spatial analysis of air pollution and mortality in California. *Am J Respir Crit Care Med*, 188, 593–599. [PubMed: 23805824]
- Jin C, Shelburne CP, Li G, Potts EN, Riebe KJ, Sempowski GD, Foster WM, & Abraham SN (2011). Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation. *J Clin Invest*, 121, 941–955. [PubMed: 21285515]
- Johnstrom P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC, Pickard JD, & Davenport AP (2005). Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. *Br J Pharmacol*, 144, 115–122. [PubMed: 15644875]
- Kaddoura S, Firth JD, Boheler KR, Sugden PH, & Poole-Wilson PA (1996). Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally

active, mixed endothelin ETA and ETB receptor antagonist. *Circulation*, 93, 2068–2079. [PubMed: 8640984]

- Kang YJ, Li Y, Zhou Z, Roberts AM, Cai L, Myers SR, Wang L, & Schuchke DA (2002). Elevation of serum endothelins and cardiotoxicity induced by particulate matter (PM_{2.5}) in rats with acute myocardial infarction. *Cardiovasc Toxicol*, 2, 253–261. [PubMed: 12665659]
- Karwadowska-Prokopczuk E, & Wennmalm A (1990). Effects of endothelin on coronary flow, mechanical performance, oxygen uptake, and formation of purines and on outflow of prostacyclin in the isolated rabbit heart. *Circ Res*, 66, 46–54. [PubMed: 2403862]
- Kawabe J, Ushikubi F, & Hasebe N (2010). Prostacyclin in vascular diseases. - Recent insights and future perspectives. *Circ J*, 74, 836–843. [PubMed: 20424334]
- Kedzierski RM, & Yanagisawa M (2001). Endothelin system: the double-edged sword in health and disease. *Annu Rev Pharmacol Toxicol*, 41, 851–876. [PubMed: 11264479]
- Kelly FJ (2003). Oxidative stress: its role in air pollution and adverse health effects. *Occup Environ Med*, 60, 612–616. [PubMed: 12883027]
- Kodavanti UP, Schladweiler MC, Ledbetter AD, Hauser R, Christiani DC, Samet JM, McGee J, Richards JH, & Costa DL (2002). Pulmonary and systemic effects of zinc-containing emission particles in three rat strains: multiple exposure scenarios. *Toxicol Sci*, 70, 73–85. [PubMed: 12388837]
- Kodavanti UP, Schladweiler MC, Gilmour PS, Wallenborn JG, Mandavilli BS, Ledbetter AD, Christiani DC, Runge MS, Karoly ED, Costa DL, Peddada S, Jaskot R, Richards JH, Thomas R, Madamanchi NR, & Nyska A (2008). The role of particulate matter-associated zinc in cardiac injury in rats. *Environ Health Perspect*, 116, 13–20. [PubMed: 18197293]
- Kodavanti UP, Thomas R, Ledbetter AD, Schladweiler MC, Shannahan JH, Wallenborn JG, Lund AK, Campen MJ, Butler EO, Gottipolu RR, Nyska A, Richards JE, Andrews D, Jaskot RH, McKee J, Kotha SR, Patel RB, & Parinandi NL (2011). Vascular and cardiac impairments in rats inhaling ozone and diesel exhaust particles. *Environ Health Perspect*, 119, 312–318. [PubMed: 20980218]
- Kohan DE (2006). The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. *Curr Opin Nephrol Hypertens*, 15, 34–40. [PubMed: 16340664]
- Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, & Barton M (2012). Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? *Life Sci*, 91, 528–539. [PubMed: 22967485]
- Krewski D, Burnett RT, Goldberg M, Hoover K, Siemiatycki J, Abrahamowicz M, & White W (2005). Reanalysis of the Harvard Six Cities Study, part I: validation and replication. *Inhal Toxicol*, 17, 335–342. [PubMed: 16020032]
- Krewski D, Burnett R, Jerrett M, Pope CA, Rainham D, Calle E, Thurston G, & Thun, (2005). Mortality and long-term exposure to ambient air pollution: ongoing analyses based on the American Cancer Society cohort. *J Toxicol Environ Health A*, 68, 1093–1109. [PubMed: 16024490]
- Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdorster G, & Ziesenis A (2002). Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. *J Toxicol Environ Health A*, 65, 1513–1530. [PubMed: 12396866]
- Krishnan RM, Adar SD, Szpiro AA, Jorgensen NW, Van Hee VC, Barr RG, O'Neill MS, Herrington DM, Polak JF, & Kaufman JD (2012). Vascular responses to long- and short-term exposure to fine particulate matter: MESA Air (Multi-Ethnic Study of Atherosclerosis and Air Pollution). *J Am Coll Cardiol*, 60, 2158–2166. [PubMed: 23103035]
- Laden F, Schwartz J, Speizer FE, & Dockery DW (2006). Reduction in fine particulate air pollution and mortality: Extended follow-up of the Harvard Six Cities study. *Am J Respir Crit Care Med*, 173, 667–672. [PubMed: 16424447]
- Langrish JP, Lundback M, Mills NL, Johnston NR, Webb DJ, Sandstrom T, Blomberg A, & Newby DE (2009). Contribution of endothelin 1 to the vascular effects of diesel exhaust inhalation in humans. *Hypertension*, 54, 910–915. [PubMed: 19687345]

- Lepeule J, Laden F, Dockery D, & Schwartz J (2012). Chronic exposure to fine particles and mortality: an extended follow-up of the Harvard Six Cities study from 1974 to 2009. *Environ Health Perspect*, 120, 965–970. [PubMed: 22456598]
- Levin ER (1995). Endothelins. *N Engl J Med*, 333, 356–363. [PubMed: 7609754]
- Li K, Stewart DJ, & Rouleau JL (1991). Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Role of endocardial endothelium. *Circ Res*, 69, 301–312. [PubMed: 1860176]
- Li N, Xia T, & Nel AE (2008). The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. *Free Radic Biol Med*, 44, 1689–1699. [PubMed: 18313407]
- Li N, Harkema JR, Lewandowski RP, Wang M, Bramble LA, Gookin GR, Ning Z, Kleinman MT, Sioutas C, & Nel AE (2010). Ambient ultrafine particles provide a strong adjuvant effect in the secondary immune response: implication for traffic-related asthma flares. *Am J Physiol Lung Cell Mol Physiol*, 299, L374–383. [PubMed: 20562226]
- Lin J, Kakkar V, & Lu X (2014). Impact of matrix metalloproteinases on atherosclerosis. *Curr Drug Targets*, 15, 442–453. [PubMed: 24517161]
- Liu L, Ruddy T, Dalipaj M, Poon R, Szyszkowicz M, You H, Dales RE, & Wheeler AJ (2009). Effects of indoor, outdoor, and personal exposure to particulate air pollution on cardiovascular physiology and systemic mediators in seniors. *J Occup Environ Med*, 51, 1088–1098. [PubMed: 19701101]
- Liu T, Qin M, Shi SB, Chen Z, Wang T, & Huang CX (2013). Effects of endothelin-1 chronic stimulation on electrical restitution, beat-to-beat variability of repolarization, and ventricular arrhythmogenesis. *J Cardiovasc Pharmacol*, 62, 549–558. [PubMed: 24084217]
- Lteif A, Vaishnav P, Baron AD, & Mather KJ (2007). Endothelin limits insulin action in obese/insulin-resistant humans. *Diabetes*, 56, 728–734. [PubMed: 17327443]
- Lueddeckens G, Bigl H, Sperling J, Becker K, Braquet P, & Forster W (1993). Importance of secondary TXA2 release in mediating of endothelin-1 induced bronchoconstriction and vasopressin in the guinea-pig. *Prostaglandins Leukot Essent Fatty Acids*, 48, 261–263. [PubMed: 8469685]
- Lund AK, Lucero J, Lucas S, Madden MC, McDonald JD, Seagrave JC, Knuckles L, & Campen MJ (2009). Vehicular emissions induce vascular MMP-9 expression and activity associated with endothelin-1-mediated pathways. *Arterioscler Thromb Vasc Biol*, 29, 511–517. [PubMed: 19150882]
- Luscher TF, & Barton M (2000). Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. *Circulation*, 102, 2434–2440. [PubMed: 11067800]
- Luscher TF, Seo BG, & Buhler FR (1993). Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. *Hypertension*, 21, 752–757. [PubMed: 8500855]
- MacNulty EE, Plevin R, & Wakelam MJ (1990). Stimulation of the hydrolysis of phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine by endothelin, a complete mitogen for Rat-1 fibroblasts. *Biochem J*, 272, 761–766. [PubMed: 2176477]
- Maguire JJ, & Davenport AP (2014). Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. *Br J Pharmacol*, 171, 5555–5572. [PubMed: 25131455]
- Maier KL, Alessandrini F, Beck-Speier I, Hofer TP, Diabate S, Bitterle E, Stoger T, Jakob T, Behrendt H, Horsch M, Beckers J, Ziesenis A, Hultner L, Frankenberger M, Krauss-Etschmann S, & Schulz H (2008). Health effects of ambient particulate matter--biological mechanisms and inflammatory responses to in vitro and in vivo particle exposures. *Inhal Toxicol*, 20, 319–337. [PubMed: 18300050]
- Malek AM, Zhang J, Jiang J, Alper SL, & Izumo S (1999). Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. *J Mol Cell Cardiol*, 31, 387–399. [PubMed: 10093051]

- Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, & Group AS (2010). Avasentan for overt diabetic nephropathy. *J Am Soc Nephrol*, 21, 527–535. [PubMed: 20167702]
- Marshall AK, Barrett OPT, Cullingford TE, Shanmugasundram A, Sugden PH, & Clerk A (2010). ERK1/2 Signaling Dominates Over RhoA Signaling in Regulating Early Changes in RNA Expression Induced by Endothelin-1 in Neonatal Rat Cardiomyocytes. *PLoS One*, 5.
- Martin-Nizard F, Houssaini HS, Lestavel-Delattre S, Duriez P, & Fruchart JC (1991). Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. *FEBS Lett*, 293, 127–130. [PubMed: 1959644]
- Masaki T, Vane JR, & Vanhoutte PM (1994). International Union of Pharmacology nomenclature of endothelin receptors. *Pharmacol Rev*, 46, 137–142. [PubMed: 7938163]
- McMahon EG, Palomo MA, Moore WM, McDonald JF, & Stern MK (1991). Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1–39) in vivo and conversion of big endothelin-1-(1–39) to endothelin-1-(1–21) in vitro. *Proc Natl Acad Sci U S A*, 88, 703–707. [PubMed: 1992461]
- McMurray JJ, Ray SG, Abdullah I, Dargie HJ, & Morton JJ (1992). Plasma endothelin in chronic heart failure. *Circulation*, 85, 1374–1379. [PubMed: 1532540]
- Mebazaa A, Mayoux E, Maeda K, Martin LD, Lakatta EG, Robotham JL, & Shah AM (1993). Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. *Am J Physiol*, 265, H1841–1846. [PubMed: 8238598]
- Medina-Ramon M, Goldberg R, Melly S, Mittleman MA, & Schwartz J (2008). Residential exposure to traffic-related air pollution and survival after heart failure. *Environ Health Perspect*, 116, 481–485. [PubMed: 18414630]
- Milara J, Ortiz JL, Juan G, Guijarro R, Almudever P, Martorell M, Morcillo EJ, & Cortijo J (2010). Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. *Br J Pharmacol*, 161, 1599–1615. [PubMed: 20698855]
- Milara J, Gabarda E, Juan G, Ortiz JL, Guijarro R, Martorell M, Morcillo EJ, & Cortijo J (2012). Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries. *Eur Respir J*, 39, 927–938. [PubMed: 21828025]
- Mills NL, Tornqvist H, Robinson SD, Gonzalez M, Darnley K, MacNee W, Boon NA, Donaldson K, Blomberg A, Sandstrom T, & Newby DE (2005). Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. *Circulation*, 112, 3930–3936. [PubMed: 16365212]
- Mitani H, Takimoto M, Bandoh T, & Kimura M (2000). Increases of vascular endothelin-converting enzyme activity and endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. *Eur J Pharmacol*, 387, 313–319. [PubMed: 10650177]
- Miyata R, Hiraiwa K, Cheng JC, Bai N, Vincent R, Francis GA, Sin DD, & Van Eeden SF (2013). Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10). *Toxicol Appl Pharmacol*, 272, 1–11. [PubMed: 23756175]
- Modesti PA, Vanni S, Panicia R, Perna A, Maccherini M, Lisi G, Sani G, & Neri Serneri GG (1999). Endothelin receptors in adult human and swine isolated ventricular cardiomyocytes. *Biochem Pharmacol*, 58, 369–374. [PubMed: 10423180]
- Moller P, Jacobsen NR, Folkmann JK, Danielsen PH, Mikkelsen L, Hemmingsen JG, Vesterdal LK, Forchhammer L, Wallin H, & Loft S (2010). Role of oxidative damage in toxicity of particulates. *Free Radic Res*, 44, 1–46. [PubMed: 19886744]
- Moller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, Haussinger K, & Kreyling WG (2008). Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. *Am J Respir Crit Care Med*, 177, 426–432. [PubMed: 17932382]
- Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, & Thuillez C (1997). Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. *Circulation*, 96, 1976–1982. [PubMed: 9323089]

- Mylona P, & Cleland JG (1999). Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. *Eur J Heart Fail*, 1, 197–200. [PubMed: 10937931]
- Namer B, Hilliges M, Orstavik K, Schmidt R, Weidner C, Torebjork E, Handwerker H, & Schmelz M (2008). Endothelin 1 activates and sensitizes human C-nociceptors. *Pain*, 137, 41–49. [PubMed: 17884295]
- Neef S, & Maier LS (2013). Novel aspects of excitation–contraction coupling in heart failure. *Basic research in cardiology*, 108, 1–11.
- Nemery B, Hoet PH, & Nemmar A (2001). The Meuse Valley fog of 1930: an air pollution disaster. *Lancet*, 357, 704–708. [PubMed: 11247570]
- Nett PC, Teixeira MM, Candinas D, & Barton M (2006). Recent developments on endothelin antagonists as immunomodulatory drugs--from infection to transplantation medicine. *Recent Pat Cardiovasc Drug Discov*, 1, 265–276. [PubMed: 18221091]
- Noireaud J, & Andriantsitohaina R (2014). Recent insights in the paracrine modulation of cardiomyocyte contractility by cardiac endothelial cells. *Biomed Res Int*, 2014, 923805.
- O'Connor CM, Gattis WA, Adams KF, Jr., Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, & Gheorghiade M (2003). Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). *J Am Coll Cardiol*, 41, 1452–1457. [PubMed: 12742280]
- Ohno N, Tanaka T, Kita T, Kubo K, Shimada K, Yonetani Y, Konishi N, & Nakashima T (2004). Changes of brain endothelin levels and peripheral endothelin receptors by chronic cigarette smoke in spontaneously hypertensive rats. *J Pharmacol Sci*, 94, 287–296. [PubMed: 15037814]
- Palmer RM, Ferrige AG, & Moncada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature*, 327, 524–526. [PubMed: 3495737]
- Peng RD, Dominici F, Pastor-Barriuso R, Zeger SL, & Samet JM (2005). Seasonal analyses of air pollution and mortality in 100 US cities. *Am J Epidemiol*, 161, 585–594. [PubMed: 15746475]
- Peretz A, Sullivan JH, Leotta DF, Trenga CA, Sands FN, Allen J, Carlsten C, Wilkinson CW, Gill EA, & Kaufman JD (2008). Diesel exhaust inhalation elicits acute vasoconstriction in vivo. *Environ Health Perspect*, 116, 937–942. [PubMed: 18629317]
- Peters A, Dockery DW, Muller JE, & Mittleman MA (2001). Increased particulate air pollution and the triggering of myocardial infarction. *Circulation*, 103, 2810–2815. [PubMed: 11401937]
- Pfuntner A, Wier LM, & Stocks C (2013). Most frequent conditions in US hospitals, 2011. *Pierre, L. N., & Davenport, A. P. (1999). Blockade and reversal of endothelin-induced constriction in pial arteries from human brain. Stroke*, 30, 638–643.
- Pieters N, Plusquin M, Cox B, Kicinski M, Vangronsveld J, & Nawrot TS (2012). An epidemiological appraisal of the association between heart rate variability and particulate air pollution: a meta-analysis. *Heart*, 98, 1127–1135. [PubMed: 22628541]
- Pope CA, 3rd, Thun MJ, Namboodiri MM, Dockery DW, Evans JS, Speizer FE, & Heath CW, Jr. (1995). Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. *Am J Respir Crit Care Med*, 151, 669–674. [PubMed: 7881654]
- Pope CA, 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, & Godleski JJ (2004). Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. *Circulation*, 109, 71–77. [PubMed: 14676145]
- Pope CA, 3rd, Turner MC, Burnett RT, Jerrett M, Gapstur SM, Diver WR, Krewski D, & Brook RD (2015). Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality. *Circ Res*, 116, 108–115. [PubMed: 25348167]
- Rahman MM, Elmi S, Chang TK, Bai N, Sallam NA, Lemos VS, Moien-Afshari F, Laher I (2007). Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release. *Vascul Pharmacol*, 46, 35–42. [PubMed: 16901763]
- Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, & Losano G (2007). Nitric oxide and cardiac function. *Life Sci*, 81, 779–793. [PubMed: 17707439]
- Resink TJ, Scott-Burden T, & Buhler FR (1988). Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. *Biochem Biophys Res Commun*, 157, 1360–1368. [PubMed: 3144974]

- Rivera M, Basagana X, Aguilera I, Foraster M, Agis D, de Groot E, Perez L, Mendez MA, Bouso L, Targa J, Ramos R, Sala J, Marrugat J, Elosua R, & Kunzli N (2013). Association between long-term exposure to traffic-related air pollution and subclinical atherosclerosis: the REGICOR study. *Environ Health Perspect*, 121, 223–230. [PubMed: 23384708]
- Ross R (1999). Atherosclerosis--an inflammatory disease. *N Engl J Med*, 340, 115–126. [PubMed: 9887164]
- Rubin LJ, & Roux S (2002). Bosentan: a dual endothelin receptor antagonist. *Expert Opin Investig Drugs*, 11, 991–1002.
- Ruetten H, & Thiemermann C (1997). Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. *J Physiol Pharmacol*, 48, 675–688. [PubMed: 9444616]
- Russell FD, & Molenaar P (2000). The human heart endothelin system: ET-1 synthesis, storage, release and effect. *Trends Pharmacol Sci*, 21, 353–359. [PubMed: 10973089]
- Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, & Sugishita Y (1996). Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. *Nature*, 384, 353–355. [PubMed: 8934519]
- Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, & Masaki T (1990). Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. *Nature*, 348, 732–735. [PubMed: 2175397]
- Saleh MA, Boesen EI, Pollock JS, Savin VJ, & Pollock DM (2010). Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. *Hypertension*, 56, 942–949. [PubMed: 20823379]
- Scharrer E, Hessel H, Kronseder A, Guth W, Rolinski B, Jorres RA, Radon K, Schierl R, Angerer P, & Nowak D (2007). Heart rate variability, hemostatic and acute inflammatory blood parameters in healthy adults after short-term exposure to welding fume. *Int Arch Occup Environ Health*, 80, 265–272. [PubMed: 16791613]
- Schwar MJ, Moorcroft JS, Laxen DP, Thompson M, & Armorgie C (1988). Baseline metal-in-dust concentrations in Greater London. *Sci Total Environ*, 68, 25–43. [PubMed: 3363319]
- Scott JA (1953). Fog and deaths in London, December 1952. *Public Health Rep*, 68, 474–479. [PubMed: 13047517]
- Shah AS, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, Newby DE, & Mills NL (2013). Global association of air pollution and heart failure: a systematic review and meta-analysis. *Lancet*, 382, 1039–1048. [PubMed: 23849322]
- Shaw SG, Schmid M, & Casty A (2000). Critical factors in the radioimmunoassay of endothelin-1, endothelin-3, and big endothelin-1 in human plasma. *Anal Biochem*, 278, 143–149. [PubMed: 10660455]
- Sidharta PN, van Giersbergen PL, & Dingemanse J (2013). Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. *J Clin Pharmacol*, 53, 1131–1138. [PubMed: 23900878]
- Sidharta PN, van Giersbergen PL, Halabi A, & Dingemanse J (2011). Macitentan: entry-into-humans study with a new endothelin receptor antagonist. *Eur J Clin Pharmacol*, 67, 977–984. [PubMed: 21541781]
- Siegemund A, Petros S, Siegemund T, Scholz U, Seyfarth HJ, & Engelmann L (2004). The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. *Blood Coagul Fibrinolysis*, 15, 241–244. [PubMed: 15060420]
- Simonson MS, & Dunn MJ (1990a). Endothelin. Pathways of transmembrane signaling. *Hypertension*, 15, 15–12. [PubMed: 2153630]
- Simonson MS, & Dunn MJ (1990b). Cellular signaling by peptides of the endothelin gene family. *FASEB J*, 4, 2989–3000. [PubMed: 2168326]
- Simonson MS, Wann S, Mene P, Dubyak GR, Kester M, Nakazato Y, Sedor JR, & Dunn MJ (1989). Endothelin stimulates phospholipase C, Na⁺/H⁺ exchange, c-fos expression, and mitogenesis in rat mesangial cells. *J Clin Invest*, 83, 708–712. [PubMed: 2536405]
- Sirivelu MP, MohanKumar SM, Wagner JG, Harkema JR, & MohanKumar PS (2006). Activation of the stress axis and neurochemical alterations in specific brain areas by concentrated ambient

- particle exposure with concomitant allergic airway disease. *Environ Health Perspect*, 114, 870–874. [PubMed: 16759987]
- Spinella MJ, Malik AB, Everitt J, & Andersen TT (1991). Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction. *Proc Natl Acad Sci U S A*, 88, 7443–7446. [PubMed: 1871142]
- Stewart DJ, Kubac G, Costello KB, & Cernacek P (1991). Increased plasma endothelin-1 in the early hours of acute myocardial infarction. *J Am Coll Cardiol*, 18, 38–43. [PubMed: 2050938]
- Szabo T, Geller L, Merkely B, Selmei L, Juhasz-Nagy A, & Solti F (2000). Investigating the dual nature of endothelin-1: ischemia or direct arrhythmogenic effect? *Life Sci*, 66, 2527–2541. [PubMed: 10883731]
- Takayasu-Okishio M, Terashita Z, & Kondo K (1990). Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells. *Biochem Pharmacol*, 40, 2713–2717. [PubMed: 2260994]
- Takenaka S, Karg E, Roth C, Schulz H, Ziesenis A, Heinzmann U, Schramel P, & Heyder J (2001). Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats. *Environ Health Perspect*, 109 Suppl 4, 547–551.
- Tarantini L, Bonzini M, Tripodi A, Angelici L, Nordio F, Cantone L, Apostoli P, Bertazzi PA, & Baccarelli AA (2013). Blood hypomethylation of inflammatory genes mediates the effects of metal-rich airborne pollutants on blood coagulation. *Occup Environ Med*, 70, 418–425. [PubMed: 23476046]
- Task Force of the European Society of Cardiology. (1996). Heart rate variability standards of measurement, physiological interpretation, and clinical use. *Eur Heart J*, 17, 354–381. [PubMed: 8737210]
- Thompson LC, Urankar RN, Holland NA, Vidanapathirana AK, Pitzer JE, Han L, Sumner SJ, Lewin AH, Fennell TR, Lust RM, Brown JM, & Wingard CJ (2014). C60 exposure augments cardiac ischemia/reperfusion injury and coronary artery contraction in Sprague Dawley rats. *Toxicol Sci*, 138, 365–378. [PubMed: 24431213]
- Thomson E, Kumarathasan P, Goegan P, Aubin RA, & Vincent R (2005). Differential regulation of the lung endothelin system by urban particulate matter and ozone. *Toxicol Sci*, 88, 103–113. [PubMed: 16081523]
- Thomson EM, Kumarathasan P, Calderon-Garciduenas L, & Vincent R (2007). Air pollution alters brain and pituitary endothelin-1 and inducible nitric oxide synthase gene expression. *Environ Res*, 105, 224–233. [PubMed: 17662977]
- Tong ST, & Lam KC (1998). Are nursery schools and kindergartens safe for our kids? The Hong Kong study. *Sci Total Environ*, 216, 217–225. [PubMed: 9646530]
- Turner MC, Krewski D, Pope CA, 3rd, Chen Y, Gapstur SM, & Thun MJ (2011). Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. *Am J Respir Crit Care Med*, 184, 1374–1381. [PubMed: 21980033]
- Upadhyay S, Stoeger T, George L, Schladweiler MC, Kodavanti U, Ganguly K, & Schulz H (2014). Ultrafine carbon particle mediated cardiovascular impairment of aged spontaneously hypertensive rats. *Part Fibre Toxicol*, 11, 36. [PubMed: 25442699]
- Upadhyay S, Ganguly K, Stoeger T, Semmler-Bhenke M, Takenaka S, Kreyling WG, Pitz M, Reitmeir P, Peters A, Eickelberg O, Wichmann HE, & Schulz H (2010). Cardiovascular and inflammatory effects of intratracheally instilled ambient dust from Augsburg, Germany, in spontaneously hypertensive rats (SHRs). *Part Fibre Toxicol*, 7, 27. [PubMed: 20920269]
- Upadhyay S, Stoeger T, Harder V, Thomas RF, Schladweiler MC, Semmler-Behnke M, Takenaka S, Karg E, Reitmeir P, Bader M, Stampfl A, Kodavanti UP, & Schulz H (2008). Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats. *Part Fibre Toxicol*, 5, 19. [PubMed: 19055790]
- US EPA. (2009). Air quality criteria for particulate matter National Center for Environmental Assessment-RTP Office.

- van Eeden SF, & Hogg JC (2002). Systemic inflammatory response induced by particulate matter air pollution: the importance of bone-marrow stimulation. *J Toxicol Environ Health A*, 65, 1597–1613. [PubMed: 12396870]
- Veniant M, Clozel JP, Hess P, & Clozel M (1994). Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. *Life Sci*, 55, 445–454. [PubMed: 8035662]
- Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, & Webb DJ (1998). Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. *Circulation*, 97, 752–756. [PubMed: 9498538]
- Vierhapper H, Wagner O, Nowotny P, & Waldhausl W (1990). Effect of endothelin-1 in man. *Circulation*, 81, 1415–1418. [PubMed: 2180594]
- Vincent R, Kumarathasan P, Goegan P, Bjarnason SG, Guenette J, Berube D, Adamson IY, Desjardins S, Burnett RT, Miller FJ, & Battistini B (2001). Inhalation toxicology of urban ambient particulate matter: acute cardiovascular effects in rats. *Res Rep Health Eff Inst*, 5–54; discussion 55–62.
- Wallenborn JG, Schladweiler MJ, Richards JH, & Kodavanti UP (2009). Differential pulmonary and cardiac effects of pulmonary exposure to a panel of particulate matter-associated metals. *Toxicol Appl Pharmacol*, 241, 71–80. [PubMed: 19679144]
- Wellenius GA, Burger MR, Coull BA, Schwartz J, Suh HH, Koutrakis P, Schlaug G, Gold DR, & Mittleman MA (2012). Ambient air pollution and the risk of acute ischemic stroke. *Arch Intern Med*, 172, 229–234. [PubMed: 22332153]
- Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T, Mitchell A, & Investigators, S. P. P. E. A. E. i. D. N. S (2009). Avenant reduces albumin excretion in diabetics with macroalbuminuria. *J Am Soc Nephrol*, 20, 655–664. [PubMed: 19144760]
- WHO. (2003). Health Aspects of Air Pollution with Particulate Matter, Ozone and Nitrogen Dioxide In. Bonn, Germany.
- WHO. (2014a). The top 10 causes of death. July 2013 Available at: who.int/mediacentre/factsheets/fs310/en/. [Last accessed: July 2014].
- WHO. (2014b). Burden of disease from the joint effects of household and ambient air pollution for 2012 WHO, Geneva.
- Wiebert P, Sanchez-Crespo A, Falk R, Philipson K, Lundin A, Larsson S, Moller W, Kreyling WG, & Svartengren M (2006). No significant translocation of inhaled 35-nm carbon particles to the circulation in humans. *Inhal Toxicol*, 18, 741–747. [PubMed: 16774863]
- Wiebert P, Sanchez-Crespo A, Seitz J, Falk R, Philipson K, Kreyling WG, Moller W, Sommerer K, Larsson S, & Svartengren M (2006). Negligible clearance of ultrafine particles retained in healthy and affected human lungs. *Eur Respir J*, 28, 286–290. [PubMed: 16641121]
- Wilker EH, Mittleman MA, Coull BA, Gryparis A, Bots ML, Schwartz J, & Sparrow D (2013). Long-term exposure to black carbon and carotid intima-media thickness: the normative aging study. *Environ Health Perspect*, 121, 1061–1067. [PubMed: 23820848]
- Wilker EH, Ljungman PL, Rice MB, Kloog I, Schwartz J, Gold DR, Koutrakis P, Vita JA, Mitchell GF, Vasan RS, Benjamin EJ, Hamburg NM, & Mittleman MA (2014). Relation of long-term exposure to air pollution to brachial artery flow-mediated dilation and reactive hyperemia. *Am J Cardiol*, 113, 2057–2063. [PubMed: 24793676]
- Wright CE, & Fozard JR (1988). Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. *Eur J Pharmacol*, 155, 201–203. [PubMed: 2907490]
- Wright JL, Sun JP, & Churg A (1999). Cigarette smoke exposure causes constriction of rat lung. *Eur Respir J*, 14, 1095–1099. [PubMed: 10596696]
- Xiao X, Wang R, Cao L, Shen ZX, & Cao YX (2015). The Role of MAPK Pathways in Airborne Fine Particulate Matter-Induced Upregulation of Endothelin Receptors in Rat Basilar Arteries. *Toxicol Sci*
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, & Masaki T (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*, 332, 411–415. [PubMed: 2451132]

- Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S, Nakajima K, Watanabe TX, Sakakibara S, Goto K, & et al. (1988). Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. *Proc Natl Acad Sci U S A*, 85, 6964–6967. [PubMed: 3045827]
- Ying Z, Xu X, Bai Y, Zhong J, Chen M, Liang Y, Zhao J, Liu D, Morishita M, Sun Q, Spino C, Brook RD, Harkema JR, & Rajagopalan S (2014). Long-term exposure to concentrated ambient PM2.5 increases mouse blood pressure through abnormal activation of the sympathetic nervous system: a role for hypothalamic inflammation. *Environ Health Perspect*, 122, 79–86. [PubMed: 24240275]
- Yoon MH, Reriani M, Mario G, Rihal C, Gulati R, Lennon R, Tilford JM, Lerman LO, & Lerman A (2013). Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. *Int J Cardiol*, 168, 1316–1321. [PubMed: 23290081]
- Yorikane R, & Koike H (1990). The arrhythmogenic action of endothelin in rats. *Jpn J Pharmacol*, 53, 259–263. [PubMed: 2200920]
- Yoshimoto S, Ishizaki Y, Sasaki T, & Murota S (1991). Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. *Stroke*, 22, 378–383. [PubMed: 1900647]
- Zhang Y, Ji X, Ku T, & Sang N (2015). Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO2, NO2, and PM2.5. *Environmental toxicology*
- Zhao J, Gao Z, Tian Z, Xie Y, Xin F, Jiang R, Kan H, & Song W (2013). The biological effects of individual-level PM2.5 exposure on systemic immunity and inflammatory response in traffic policemen. *Occup Environ Med*, 70, 426–431. [PubMed: 23322918]
- Zhu BQ, Sun YP, Sudhir K, Sievers RE, Browne AE, Gao L, Hutchison SJ, Chou TM, Deedwania PC, Chatterjee K, Glantz SA, & Parmley WW (1997). Effects of second-hand smoke and gender on infarct size of young rats exposed in utero and in the neonatal to adolescent period. *J Am Coll Cardiol*, 30, 1878–1885. [PubMed: 9385922]
- Zolk O, Quattke J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, & Bohm M (1999). Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. *Circulation*, 99, 2118–2123. [PubMed: 10217651]

Figure 1.

Schematic drawing of potential ET-1 production and function in the heart following PM exposure. ET-1 is released by both endocardial/myocapillary endothelial cells and cardiomyocytes and functions as an autocrine/paracrine signaling agent. ET-1 signaling affects the release of secondary autocrine/paracrine factors, such as thromboxane A2 (TXA2), prostacyclin (PGI2), and NO. Changes in the concentrations of both primary and secondary autocrine/paracrine agents is likely important within the interstitium, though some changes can be observed in the circulation. Together, ET-1, increased TXA2, and reduced PGI2 and NO promote increased cardiac arrhythmias, positive cardiac inotropy, and positive cardiac chronotropy.

Table 1.

Detailed information about studies assessing the relationship between ET-1 concentrations, cardiac function, and PM exposure listed chronologically.

Reference	Species	Exposure	PM-mediated changes in ET	PM-mediated changes in cardiac function
Haak et al., 1994	Humans (n=10)	Low- and high-tar cigarettes	Increased circulating ET-1 levels within 10 minutes of smoking a high-tar cigarette	Increased HR after smoking a high-tar cigarette
Zhu et al., 1997	Rats (Neonatal and adolescent)	Smoke from 96 cigarettes for 6 hours per day for 5 days each week over 3 weeks, either in utero or as neonates	Increased circulating ET-1 levels after neonatal exposure	Increased infarct size after neonatal exposure
Vincent et al., 2001	Rats	Nose-only EHC-93 at 49 mg/m ³ for 4 hours, with or without (EHC-93L) soluble components; 5 mg/m ³ diesel soot; 3 mg/m ³ carbon black	EHC-93 and EHC-93L increased circulating ET-1 at 32 and 2 hours after exposure, respectively	No change in HR
Kang et al., 2002	Rats	Intratracheal instillation of 2 mg PM _{2.5} (Ying, Xu, et al., 2014)	Increased circulating ET-1 peptide 2 hours after installation; Increased ET _A R on cardiomyocytes in the infarct myocardium	Decreased HR, worsened arrhythmia, and premature ventricular contractions
Campen et al., 2006	Mice (ApoE ^{-/-})	Whole-body gasoline emissions at 60 µg/m ³ PM, with or without particles, during a 6 hour per day exposure over 3 days	Increased circulating ET-1 levels with and without particulate-containing gasoline exhaust	T-wave deviation after to exposure to gasoline exhaust Containing particulates only; No change in HR
Scharrer et al., 2006	Humans (n=20)	~3.5 mg/m ³ of steel welding fumes for 1 hour and assessed 5 hours later	Decreased circulating ET-1 levels	No change in HR or HRV
Ito et al., 2008	Rats	1–2 µg/m ³ PM _{2.5-1} CAPs for 4.5 hours per day for 4 days per season, totaling 2–3.5 mg CAPs per season	Increased <i>Et_gr</i> and <i>Et-1</i> mRNA in the heart; No change of <i>Et-1</i> mRNA in the lungs	No change in HR
Upadhyay et al., 2008	Rats (WT and SHR)	172 µg/m ³ of PM _{0.1} for 24 hours assessed 3 days later	Increased <i>Et-1</i> , <i>Et_gr</i> , and <i>Et_{pr}r</i> mRNA levels in the lungs, but not in the heart	Increased HR and decreased HRV
Brook et al., 2009	Humans (n=31)	130 µg/m ³ PM _{2.5} CAP + 109 ppb O ₃ from Toronto for 2 hours on 3 occasions	Insignificant increase immediately after exposure; Significant increase after FA exposure	Decreased HRV
Liu et al., 2009	Humans (n=28)	Environmental exposure to PM _{2.5} and black carbon	Increased circulating ET-1 levels associated with indoor PM _{2.5}	Increased HR associated with personal, indoor, and outdoor PM _{2.5}
Upadhyay et al., 2010	Rats (WT and SHR)	Intratracheal instillation of 500 and 1000 µg PM _{2.5} CAPs	Increased ET-1 peptide in the heart; Decreased ET-1 peptide in the lungs	Decreased HR after 1000 µg CAPs
Gentner et al., 2012	Rats	Secondhand cigarette smoke from 3 cigarettes over a 1 hour exposure period every day for 28 days	No change in circulating ET-1 levels	Decreased HR
Järvelä et al., 2013	Humans (n=20)	1.5–35 mg/m ³ (average 4 mg/m ³) of steel welding fumes for an 8 hour work day	No change in circulating ET-1 levels	No change in HRV
Thompson et al., 2014	Rats	Intratracheal instillation of 10 or 100 µg multi-walled carbon nanotubes	Increased circulating ET-1 in the coronary effluent	Increased arrhythmia and infarct size
Upadhyay et al., 2014	Rats (Aged SHR)	~180 µg/m ³ of UF carbon particles for 24 hours	ET-1 mRNA increased in the lungs and the heart; ETR mRNA increased in the lungs	Increased HR and decreased HRV

Reference	Species	Exposure	PM-mediated changes in ET	PM-mediated changes in cardiac function
Zhang et al., 2015	Mice	Low (0.5 mg/m ³ SO ₂ , 0.2 mg/m ³ NO ₂) and high (3.5 mg/m ³ SO ₂ , 2 mg/m ³ NO ₂) exposures 6 hours per day for 28 days with 1 or 10 mg/kg PM _{2.5} intranasal instillation every other day	ET-1 mRNA and peptide increased in cardiac tissue after high exposure	Increased HR after both exposures

CAPs, concentrated ambient particles; ET-1, endothelin-1; FA, filtered air; HR, heart rate; HRV, heart rate variability; NO₂, nitrogen dioxide; O₃, ozone; PM, particulate matter; SHR, spontaneously hypertensive; SO₂, sulfur dioxide; UF, ultrafine.

Table 2.

Evidence for ET-1 involvement in cardiac dysfunction following PM exposure.

Heart Rate (10 studies)	$\uparrow$ HR (4 studies)	$\uparrow$ ET-1 (3 studies)	Haak et al., 1994 [‡]
			Liu et al., 2009 [‡]
			Upadhyay et al., 2014 [‡]
		NC in ET-1 (1 study)	Upadhyay et al., 2008 [‡]
	$\downarrow$ HR (4 studies)	$\uparrow$ ET-1 (3 studies)	Kang et al., 2002 [‡]
			Upadhyay et al., 2010 [‡]
			Zhang et al., 2015 [‡]
		NC in ET-1 (1 study)	Gentner et al., 2012 [‡]
	NC in HR (3 studies)	$\uparrow$ ET-1 (2 studies)	Vincent et al., 2001 [‡]
		$\downarrow$ ET-1 (1 study)	Ito et al., 2008 [‡]
			Scharrer et al., 2006 [‡]
Heart Rate Variability (5 studies)	$\uparrow$ HRV (3 studies)	$\uparrow$ ET-1 (1 study)	Upadhyay et al., 2014 [‡]
		NC in ET-1 (2 studies)	Upadhyay et al., 2008 [‡]
			Brook et al., 2009 [‡]
	NC in HRV (2 studies)	NC in ET-1 (1 study)	Järvelä et al., 2013 [‡]
		$\downarrow$ ET-1 (1 study)	Scharrer et al., 2006 [‡]
Arrhythmia (3 studies)	$\uparrow$ arrhythmia (3 studies)	$\uparrow$ ET-1 (3 studies)	Kang et al., 2002 [‡]
			Campen et al., 2006 [‡]
			Thompson et al., 2014 [‡]
Myocardial Infarction (2 studies)	$\uparrow$ infarct size (2 studies)	$\uparrow$ ET-1 (2 studies)	Zhu et al., 1997 [‡]
			Thompson et al., 2014 [‡]

[‡]Animal subjects[‡]human subjects

NC, no change

 $\uparrow$ increase $\downarrow$ decrease

HR, heart rate

HRV, heart rate variability

Table 3.

Evidence that ETR antagonism alters PM effects

Exposure	ETR-mediated functional effect	Reference
CAPs	Diastolic BP	Brook
Cigarette smoke	Cell proliferation in the airways and arterial vasculature of the lung	Dadmanesh et al., 1997 [†]
	ET _B R expression	Huang et al., 2013 [†]
	Aortic and carotid artery contraction	Rahman et al., 2007 [†]
	ETR expression	Milara et al., 2012 [‡]
	Lung inflammation	Bhavsar et al., 2008 [†]
	Neutrophil recruitment to the lungs	Bhavsar et al., 2008 [†]
	Spermatogonia and spermatocyte number	Aslani et al., 2015 [†]
Cigarette smoke extract	Airway resistance	Wright et al., 1999 [†]
	ET _B R expression	Milara et al., 2010 [‡]
	Apoptosis and inflammatory cytokine production	Chen et al., 2010 [†]
Diesel exhaust	ET _A R-mediated vasoconstriction	Langrish et al., 2009 [‡]
	ET _B R-mediated arterial constriction	Cherng et al., 2009 [†]
Gasoline exhaust	MMP-9, MMP-2, ROS, and ET-1 expression in the vasculature	Lund et al., 2009 [†]

[†]Animal model[‡]human model

BP, blood pressure; CAPs, concentrated ambient particles; CS, cigarette smoke; DE, diesel exhaust; ET-1, endothelin-1; ET_BR, endothelin B receptor; ETR, endothelin receptor; HR, heart rate; MMP, matrix metalloproteinase; ROS, reactive oxygen species